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MAPK SURVIVAL SIGNALING IN MELANOMA

Matthew W. VanBrocklin, Ph.D.
Western Michigan University, 2007

Extracellular signals activate mitogen-activated protein kinase (MAPK)
cascades potentiating biological activities such as cell proliferation, differentiation,
and survival. Constitutive activation of MAPK signaling pathways is implicated in
the development and progression o f many human cancers, including melanoma.
i

Mutually exclusive activating mutations in NRAS or BRAF are found in ~85% of all
melanomas resulting in constitutive activation of the MAPK pathway (RAS-BRAFMEK-ERK-RSK). We have previously demonstrated that inhibition of this pathway
with small molecule MEK inhibitors selectively induces apoptosis in human
melanoma cells both in vitro and in vivo, but not in normal melanocytes. These
results support the notion that the MAPK pathway represents a tumor-specific
survival signaling pathway in melanoma, and that targeting members o f this pathway
may be an effective therapeutic intervention strategy for treating melanoma.
Understanding the mechanisms by which constitutive MAPK activation promotes
survival and defining the minimal vital MAPK pathway components required for the
development

and progression of melanoma may have direct translational

implications.

The overall objective of this Doctoral Thesis was to define the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

molecular mechanism(s) by which the MAPK pathway mediates melanoma-specific
survival signals. In doing so, several new promising therapeutic targets (Bcl-2, BclxL and Mcl-1) have emerged and a novel small molecule inhibitor (TW37) o f these
has been developed. Combined targeting of MAPK and these Bcl-2 pro-survival
members was synergetic in vitro and in vivo. Additionally, the ability o f RAS, BRAF
and RSK to transform normal mouse melanocytes was evaluated revealing that
NRAS and BRAF are very efficient while RSK required secondary genetic events for
progression. Upon investigation, high level intrachromosomal gene amplification of
Met, a growth factor receptor tyrosine kinase implicated in melanoma progression.
MET expression is rarely detected in primary human melanoma, but is frequently
observed in advanced metastatic disease and therefore may be an additional attractive
therapeutic target to prevent disease progression.
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CHAPTER I
INTRODUCTION
Skin Anatomy and Pigmentation
The skin is the largest organ in the body and performs many essential
functions. It consists of three layers; the epidermis (outermost), dermis and the
subcutis. The thin epidermis layer consists primarily of keratinocytes which originate
in the basal layer from the division of keratinocyte stem cells. These cells gradually
undergo differentiation as they are pushed to the stratum comeum, the outermost
layer o f the epidermis.

There they form an effective barrier o f dead highly

keratinized squamous cells which are continuously shed. The dermis consists of
connective tissue as well as hair follicles, nerves and various glands and is tightly
connected to the epidermis by a basement membrane. The thicker subcutis primarily
serves as an insulator and energy storage reservoir as it is primarily composed of
adipose tissue.
Neural crest derived melanocytes comprise 5 to 10% o f the cells in the
epidermal layer and reside near the basal layer where they obtain growth factors
derived from keratinocytes.

Melanocytes are migratory cells that produce the

pigment melanin, which is responsible for skin, hair, and eye color. The amount of
melanin produced by the melanocytes is regulated by genetic as well as
environmental factors such as UV irradiation, which stimulates melanin formation as
a protective response and results in the formation of a tan (1). In humans the variety

1
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of skin color is the result of differences in basal melanin production rather than net
differences in melanocyte number or melanocyte stimulating hormone (MSH) levels
(1). Small nucleotide polymorphisms (SNPs) in the MSH receptor, MC1R, as well as
cell surface density plays a crucial role in melanin production and the distinct
pigmentation o f each ethnic group and race (1, 2). Melanin is exported to nearby
keratinocytes resulting in uniform skin color, but can localize to produce freckles,
birthmarks or nevi (moles).
The inability of melanocytes to produce adequate melanin results in little or
no pigment in the eyes, skin or hair and is identified as albinism. There is a broad
range of pigment loss depending on the genetic defect involved, with tyrosinaserelated defects being the most common and exhibiting some of the most severe
phenotypes. In addition to pigment loss, all people with albinism exhibit some form
of vision impairment, and interestingly the primary test for albinism is an eye exam.
Albinism is distributed relatively evenly across all races and people with albinism
generally live normal life spans with comparable medical problems as their
counterparts.
In contrast, vitiligo is a chronic skin condition characterized by the localized
loss of skin pigment resulting in irregular pale patches. These de-pigmented patches
typically appear on the extremities and are often symmetric. De-pigmentation is a
result of melanocyte loss due to autoimmune or inflammatory disorders and generally
worsens over time.

Immune modulation by corticosteroids is the most common

approach to treatment, although new therapies employed to promote melanocyte
repopulation are rapidly becoming available.

2
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Skin Cancer and Melanoma Epidemiology
Not surprisingly skin cancer is the most common form of malignancy in the
United States with more than 1.5 million new cases diagnosed annually (3). Skin
cancers generally develop in the epidermis making them highly visible which allows
for early detection. Basal cell carcinoma (BCC) alone accounts for more than 1
million new cases annually, while more than 250,000 people develop squamous cell
carcinoma (SCC). BCCs are derived from basal cells that line the deepest layer o f the
epidermis and are generally found in areas of the body that are most frequently
exposed to the sun. SCC develops from squamous cells on the periphery o f the skin
and like BCC often arises in sun exposed areas, but may also develop in areas o f the
skin that may have been burned or exhibit chronic inflammation. BCC and SCC
incidence increases approaching the equator. The lifetime risk of developing these
skin cancers is about one in five for all Americans and one in three for Caucasians.
Fortunately, these types of neoplasms rarely metastasize, are easily treated by
surgical resection and are associated with a low morbidity.
Although melanoma only accounts for 4% of all skin cancers, it is responsible
for 79% of skin cancer deaths and early diagnosis is critical to the successful
treatment of the disease. Five-year relative survival rates for localized or metastatic
melanoma is 99% and 15%, respectively (4). Unfortunately, the incidence of
melanoma is increasing rapidly in the U.S. and is now the sixth most common cancer
overall in men and women with a predicted 59,940 new cases diagnosed in 2007 (4).

3
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Currently melanoma is the most common cancer in men and women ages 20-29 and
is the leading cause of cancer death in women between the ages of 25-29 (5).
Nevi

are

clusters

o f pigmented

cells

(primarily

melanocytes

and

keratinocytes) that often appear as small, dark brown spots on the torso, face, arms
and legs which can give rise to melanoma. Melanoma is a malignant neoplasm which
originates from the melanocytes.

Melanomas most often arise within epidermal

melanocytes of the skin, although they can also derive from noncutaneous
melanocytes such as those lining the choroidal layer of the eye and internal organs
(2). Most melanomas are black or brown, but can range from skin-colored to pink, red
or purple. Accurate diagnosis of melanoma requires experience, as early stages may
look identical to harmless moles or not have any color at all. As with most cancers,
early detection is paramount for enhanced survival.

Likely due to its migratory

history, melanomas are highly metastatic resulting in high mortality.
There are several factors, both environmental as well as genetic, that can
contribute to an increased risk for melanoma.

Probably the most important

environmental factor that can lead to an increased risk of melanoma is exposure to
sun light. Over the past 60 years there has been a dramatic increase in the melanoma
rate in the U.S. due to the increase in skin exposure to sun light that has become
culturally desirable. In 1940, when conservative clothing was in vogue, the lifetime
risk o f developing melanoma in the U.S. was 1 in 1,500 which contrasts sharply with
a 2007 predicted rate of 1 in 67 (4, 5). High incidences o f skin cancer are also seen in
other countries with substantial sun exposure and a fair skinned population such as
Australia.

Australia has the highest melanoma incidence world wide where the
4
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immigrant white population is 3 to 5 times more likely to develop melanoma than
their American or European counterparts (6).
Although sun exposure is a major contributing factor to melanoma
development its effects can be mitigated by skin pigmentation. Therefore, race is a
major risk factor for developing melanoma with fair-skinned races at greater risk than
darker-skinned races. White Americans are 4 and 20 times more likely to develop
melanoma than Hispanic and African Americans, respectively and worldwide white
populations have the highest risk of developing melanoma.

Interestingly, Asian

populations have the lowest risk (7). In addition to race, additional relevant risk
factors include a fair complexion, red hair, atypical or dysplastic nevi and increased
numbers o f nevi (8).
Several genetic components have been associated with an increased incidence
of melanoma. In 1857, William Norris identified individuals with a family history of
melanoma (9) and it is now well established that a family history of the disease can
be considered a risk factor although familial forms represent less than 10% of all
cases.

Familial melanomas share similar histopathology and survival rates with

sporadic melanoma (1, 8) but individuals with a family history will generally have a
greater number of primary lesions that will develop at an earlier age. Although three
genes involved in familial melanoma have been well characterized, they are only
present in 40% of all familial melanomas and mutations in these genes are not always
predictive.
Germline activating mutations in cyclin-dependent kinase 4 (CDK4), located
on chromosome 12ql3, are inherited in an autosomal dominant fashion and confer the
5
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highest risk (1).

CDK4 is important in regulating cell cycle progression.

The

CDKN2A locus encodes the remaining two susceptibility genes, which encode two
distinct tumor suppressor proteins:

Inhibitor of cyclin-dependent kinase 4A

(pl6iNK4a) involved in suppressing cell cycle progression and alternate reading frame
(p 14a rf) a key regulator of the p53 tumor suppressor pathway. Alternative splicing
results in two different gene products, but due to their overlapping coding regions the
prevalence of each is equal. CDK4 and p lb 11^ 43 / p l4 ARF mutations are mutually
exclusive (2). With greater frequency, non-germline mutations in these genes are
found in sporadic melanoma (2).
Rare non-familial genetic disorders lacking racial bias can be the single
greatest risk factor for developing melanoma. Xeroderma pigmentosum (XP) is an
autosomal recessive genetic disorder characterized by an inability to correctly repair
DNA damage caused by UV. Mutations in nucleotide excision repair (NER) genes
are the leading cause o f XP and results in diminished or inability to repair damaged
DNA. Chronic exposure to UV leads to an accumulation of DNA damage ultimately
resulting in oncogenesis.

In fact, people with XP have a 1,000-fold increase in

melanoma incidence with a median onset at 8 years with less than 40% surviving past
20 years (10).

In contrast, melanoma occurrence in albinos is extremely rare

(11), likely due to a combination of diligent sun avoidance as well as a lack o f UVAmelanin intracellular interactions creating free radicals leading to sustained DNA
damage in melanocytes.

6
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Melanoma Classification
There are four subtypes of cutaneous invasive melanoma (12). This includes
superficial spreading, which accounts for 70% o f all cases in the U.S., and is
generally located on the lower extremities or back and may appear variably
pigmented with a flat or slightly elevated papule with an irregular contour (13).
Nodular melanomas generally present as deeply pigmented, small asymmetric
nodules on the neck or trunk. Lentigo maligna melanoma (dermis) arises from pre
existing lentigo maligna lesions on the face of the elderly and are deeply pigmented
and form slow growing nodules. Acral letiginous melanoma accounts for less than
5% of all melanomas in caucasions, but is six times more prevalent in African
Americans and Asians (14). It is characterized by its appearance and location as
deeply pigmented lesions that appear as deep nodules on the palms, soles, fingers,
toes and nails.
Melanoma is one of a handful of cancers that are staged in millimeters rather
than centimeters due to its very aggressive nature (2).

In 1969, the staging of

cutaneous melanoma was established by Dr. Wallace Clark and was based on
dimension, ulceration, lymph node involvement, and distant metastases (15). There
are two important growth phases involved in melanoma progression; radial growth
phase (RGP) and vertical growth phase (VGP). During RGP, pagetoid spread of
melanocytes occurs and is an early indicator of a precancerous state.

Most

melanomas undergo RGP for months to years followed by progression into the often
very rapid VGP which promotes metastasis to nearby lymph nodes and beyond (16).
Clark Level staging was recently updated in 1997 and again in 2001 by the American
7
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Joint Committee on Cancer to include tumor-node-metastasis (TNM) criteria
consistent with outcome (17). Like most cancers, there are four distinct stages (I-IV)
that can be further subdivided (A-C).

Table 1 shows the staging categories for

cutaneous melanoma.

Table 1. Current AJCC Staging System for Cutaneous Melanoma
Stage JCharacteristics
IA

Tumor <1.0 mm without ulceration; no lymph node involvement; no distant
metastases

IB

Tumor <1.0 mm with ulceration or Clark level IV or V; tumor 1.01-2.0 mm
without ulceration; no lymph node involvement; no distant metastases

1IIA

Tumor 1.01-2.0 mm with ulceration; tumor 2.01-4.0 mm without ulceration;
no lymph node involvement; no distant metastases

;IIB

jTumor 2.01-4.0 mm with ulceration

IIIB
i

ITumor > 4.0 mm without ulceration; no lymph node involvement; no distant
metastases

| IIC

iTumor > 4.0 mm with ulceration; no nodal involvement; no distant metastases

j IIIA jTumor of any thickness without ulceration with 1 positive lymph
IIIIB {Tumor of any thickness without ulceration with 2-3 positive lymph nodes
i IIIC iTumor of any thickness and 4 more metastatic lymph nodes OR matted nodes
i
j OR in-transit met(s)/satellite(s) without metastatic lymph nodes, or
]combinations of in-transit met(s)/satellite(s), OR ulcerated melanoma and
jmetastatic lymph node(s)
IV

]Tumor of any thickness with any nodes and any distant metastases

Met(s) = metastases, Ulceration = the absence of an intact epidermis overlying a
portion of the primary melanoma based on pathologic microscopic observation of the
histologic sections. Source: Adapted from Balch et al., 2001 (17).

Etiology
It is well established that ultraviolet A and B (UVA, UVB) exposure plays a
crucial role in promoting all skin cancers including melanoma.

All skin cancer

8
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frequencies increase approaching the equator where more direct UV rays are present.
Occasional extreme sun exposure resulting in blistering or peeling sunburns greatly
enhances the likelihood of developing melanoma, especially prior to age 20 (18).
These individuals are twice as likely to develop melanoma as people who work
outdoors (18). Gradual sun exposure and tan formation protects melanocytes from
the DNA damaging effects of UVA and UVB.
UVB radiation induces DNA damage to cells by causing covalent bonds to
form between adjacent thymine bases. This can result in thymine dimer formation,
often resulting in misrepair and mutagenesis and/or DNA strand breaks. When basal
or squamous cells accrue chromosomal damage, the cells often die or form a
nonmalignant neoplasm, such as BCC or SCC. In contrast, these types of mutations
are rarely found in melanomas (19). Unlike most cell types in the skin, melanocytes
are highly resistant to the cytotoxic effects of UVA and UVB radiation and are able
to survive to produce melanin to neutralize the effects o f future radiation exposure
(20). The ability to endure frequent or severe UVA and UVB exposure allows some
melanocytes, especially those clustered in nevi, to accrue UV-induced genetic
alterations over time leading to the development o f melanoma.
While many genetic alterations have been identified at all stages in
melanomagenesis, mutations in several proto-oncogenes have been found with a high
frequency.

This includes mutually exclusive mutations in NRAS and BRAF,

resulting in constitutive activation of the mitogen-activated protein kinase (MAPK)
signaling pathway in over 70% of all malignant melanomas (21). Additionally, most
of those harboring BRAF mutations also have PTEN loss which results in AKT
9
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signaling deregulation.

These two vital signal transduction pathways promote

melanoma cell survival and proliferation and promote keratinocyte independence
enabling metastasis.

Current Therapies
Complete surgical excision with large margins, often reaching 2 cm, and local
nodal biopsy is the standard therapy for cutaneous melanomas. Surgery remains the
best treatment for localized melanomas with a cure rate approaching 100%. Similar
to most cancers, melanoma generally spreads to local lymph nodes prior to
metastasizing to other organs such as the lung, liver or brain. Stage III patients with a
melanoma positive lymph node generally undergo radical lymphadenectomy followed
by adjuvant therapy, but still have a poor prognosis (22). Stage IV patients with
established metastatic melanoma undergo surgery for the primary tumor (if known)
followed by aggressive adjuvant care (22).

Melanoma is also one o f the most

common metastatic cancers of unknown primary lesion (2). Cure rates for metastatic
disease has seen little increase over the last 30 years (23).
Currently Dacarbazine (DTIC), an alkylating agent, is the only FDA approved
chemotherapeutic agent for treating melanoma. Temolozomide is a related drug, but
can be taken orally and is often used in place of DTIC. There are many clinical trials
that use compounds in combination with DTIC or Temolozomide.

Two

immunotherapeutic cytokines are also approved for the treatment o f Stage II - IV
melanoma. While interferon gamma (IFNy) has a poor overall long term success rate
and is associated with unfavorable side effects, some patients are spontaneously cured
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(24). Recently IL-2, another inflammatory cytokine, was approved for the treatment
of metastatic melanoma and has shown a similar pattern of response as IFNy. While
the response rates are lower for these immunotherapeutics, most patients that do
respond have a complete remission that is long-lasting (24). While melanomas are
much less sensitive to the apoptosis-inducing effects of radiation, occasionally
radiation treatment is the preferred treatment. Often this method is used to treat large
(slower growing) facial lentigo melanomas in older patients as opposed to radical
surgery. Radiation is generally the best way to target melanoma that has metastasized
to the brain.

Promising Clinical Trials
It is quite clear that current therapies used to treat metastatic melanoma are
inadequate as the 5-year survival rate has remained at less than 15% for decades with
over 8,000 deaths annually (4). Current therapies are not target-specific, but most of
the new promising therapies are. By far, the most numerous clinical trials are based
on the immunogenecity of melanoma specific antigens. While IFNy and IL-2 nonspecifically activate lymphocytes, most vaccine therapies incorporate small known
antigenic melanoma-specific peptides to “educate” the host lymphocytes and direct
their activity towards melanomas systemically.
Unfortunately, all of these trials to date have failed to produce a significant
survival benefit relative to standard therapies. Most patients respond initially and
then quickly progress. Recently, Antigenics presented the results from a Phase III
clinical trial of Oncophage (Vitespen) in metastatic melanoma at the annual American
11
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Society of Clinical Oncology (ASCO) meeting. After surgery, the patient’s tumors
were sent to Anitgenics where isolation and purification of heat shock protein 96
(HSP96) and bound peptides occured. This tailored vaccine was then reintroduced
into the patient to invoke a melanoma-specific immune response. Initial results are
promising, especially in pre-stage IV patients where a 50% increase in survival over
standard therapy was observed (25).
Targeted therapies based on exploiting prevalent mutations of specific kinases
are also increasing as reagents become available. O f note, small molecule inhibitors
of the RAS/MAPK pathway have shown promise in early phase I and II clinical trials.
While mutations in RAS are prevalent in most cancer types resulting in constitutive
MAPK signaling, inhibition of this pathway has little effect on tumor growth, except
in melanoma (26-28). BRAF and NRAS mutations are nearly as prominent in nevi as
in melanomas and are likely involved in initiating melanomagenesis, but still required
for survival. Recent in vitro data suggests that MAPK and AKT appear to be vital for
melanoma survival (26, 27). Trials involving multiple inhibitors of the MAPK and
AKT pathway are currently underway. Targeting cellular components that regulate
apoptosis such as the Inhibitor of Apoptosis (IAP) and Bcl-2 family members has
recently gained traction as small molecule antagonists. For example, ABT737
developed by Abbott, which targets Bcl-2/Bcl-xL, or the inhibitor YM155 developed
by Astellas Pharma, which targets most IAPs including survivin, have recently been
developed and are currently in early phase clinical trials.

The rationale for this

approach is to reduce the threshold of stress (through chemotherapy, etc.) required to
induce apoptosis. Despite obvious delivery hurdles to overcome, Oblimersen (Bcl-2
12
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antisense DNA molecule) showed much promise in a Phase III clinical trial in
combination with DTIC (29).

Discussion
Developing rational therapeutic targets (genetic and immunogenic) in
melanoma is now a possibility as better small molecule agents become available.
Like all cancers, though, many genetic mutations are found in melanomas at various
stages.

It will be necessary to ‘sift’ through these to find those required for

progression, metastasis, and maintenance. Simultaneously, alterations in melanocyte
specific melanin production occur during this progression, resulting in altered
appearance in color and antigenicity. It will likely be necessary to target several vital
components simultaneously (genetic and/or immunogenic), but most current clinical
trials involve single agent therapies rather than true combinational therapies.
Supportive of this notion are the results from the Oncophage (Vitespen) clinical trial.
Probably the best characterized melanoma antigen is gplOO (highly antigenic), which
has been targeted extensively immunologically in clinical trials with very little long
term success.

Oncophage vaccine therapies use many patient melanoma-specific

uncharacterized antigens to stimulate an immune response.

Similar responses are

observed when patient’s dendritic cells are removed, exposed to melanoma antigens
in the presence of cytokines, expanded and returned to the patient. However, the
latter process is expensive and time consuming.
True combination therapies targeting genetic alterations and/or apoptosis
regulation are also necessary. Targeting MAPK and Bcl-2 pro-survival members
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simultaneously resulted in complete regression o f human melanomas resistant to
inhibition of either target alone (30). Unfortunately most of these new agents are
evaluated as a single agent therapy. Given the high costs associated with clinical
trials and FDA approval, another issue facing melanoma and other less prevalent
cancers (smaller market potential) is the commitment from pharmaceutical
companies. Pfizer, for example initiated a large clinical trial with the small molecule
MEK inhibitor C l-1040 directed against pancreatic, breast, colon and lung cancer
although in vitro data supported melanoma as a much better candidate. The large
clinical trial failed, ended abruptly, and Pfizer only recently initiated a phase II
clinical trial targeting melanoma with a second generation Cl-1040 derivative, which
has shown very promising results.

The real challenge will be convincing

pharmaceutical companies to initiate clinical trials together with their respective
novel compounds with intellectual property and associated patents.
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CHAPTER II
DIFFERENTIAL ONCOGENIC POTENTIAL OF ACTIVATED RAS ISOFORMS
IN MELANOCYTES
This work appeared in Oncogene advance online publication, 5 February 2007.
Abstract
RAS genes are mutated in approximately 30% o f all human cancers. Interestingly,
there exists a strong bias in favor of mutation of only one of the three major RAS
genes in tumors of different cellular origins. NRAS mutations occur in approximately
20% of human melanomas, while HRAS and KRAS mutations are rare in this disease.
To define the mechanism(s) responsible for this preference in melanocytes, we
compared the transformation efficiencies of mutant NRAS and KRAS in immortal,
non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased
cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does
not enhance melanocyte proliferation and is only weakly tumorigenic on its own.
While both NRAS and KRAS activate MAPK signaling, only NRAS enhances MYC
activity in these cells. Our data suggests that the activity of specific RAS isoforms is
context dependent and provides a possible explanation for the prevalence o f NRAS
mutations in melanoma. In addition, understanding this mechanism will have
important implications for cancer therapies targeting RAS pathways.
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Introduction
Molecular analysis of melanoma has identified specific genomic loci
implicated in the genesis and progression of melanoma. A significant percentage of
both familial and sporadic melanomas have mutations that functionally inactivate the
tumor suppressor genes INK4a/ARF (1). Activated NRAS oncogenes, which activate
mitogen-activated protein kinase (MAPK) signaling, have been detected in
approximately 20% of human melanomas (2). Moreover, expression of either an
NRAS or HRAS oncogene in the melanocytes of Ink4a/Arf-deficient mice results in
the formation of melanoma in 90% or 50% of the animals, respectively, by six
months o f age (3, 4). Recently, activating mutations in the BRAF gene, which also
activates MAPK signaling, have been found in a high percentage (> 65%) of
melanomas (5). With mutually exclusive mutations in RAS and BRAF, the MAPK
signaling pathway is activated in over 85% o f melanomas, indicating the importance
of the RAS/MAPK pathway in melanomagenesis.
The RAS subfamily consists of Harvey(H)-RAS, neuroblastoma(N)-RAS, and
two splice variants of Kirsten(K)-RAS (KRAS4A and KRAS4B). The RAS isoforms
share a high degree o f homology. The main differences between the isoforms are in
the C-terminal hypervariable region, which contains the membrane targeting domain
(6). HRAS and NRAS co-localize to lipid rafts, whereas KRAS is excluded from lipid
rafts and localizes to the disordered plasma membrane (7).

Differences in the

hypervariable regions correlate with functional differences of the RAS isoforms in
mammary epithelial cells (8), whereas sequences between amino acids 84 and 143 are
responsible for the greater transforming capabilities of HRAS in fibroblasts.
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Interestingly, NRAS shows greater activity in hemopoietic cells (9). Moreover, while
NRas and HRas are dispensable for mouse development both alone and in
combination (10, 11), mice that are completely devoid of KRas expression are
embryonic lethal (12). These data suggest that there are specific non-redundant
functions of the RAS proteins in different cell types. However, the mechanism(s)
underlying the biological differences between the RAS isoforms remain unclear.
In many tumors, oncogenic mutations have been identified at positions 12, 13,
or 61, which cause RAS to remain constitutively active. With the exception of thyroid
cancers, most tumors are associated with mutation of only one isoform of RAS and
this association cannot be explained solely on differential regulation of RAS gene
expression in different tissues (8). While approximately 20% of human melanomas
have been found to harbor NRAS mutations, HRAS and KRAS mutations are rare
(<1%) (2). Interestingly, several reports have demonstrated that transformation of
certain cells by specific RAS isoforms requires cooperation by a second oncogene
such as MYC (13, 14). However, the mechanism responsible for this cooperation has
not been elucidated in melanocytes.
Here we report the isolation and characterization of a non-transformed,
immortal /«&4aZ47^-deficient mouse melanocyte cell line, which was used to delineate
the mechanism(s) responsible for the prevalence o f NRAS mutations in melanocytes.
We found that expression of mutant V12-NRAS increased the rate of proliferation of
the melanocytes and was more potently transforming compared with melanocytes
expressing V12-KRAS. The increased rate of proliferation was due to the ability of
NRAS (but not KRAS) to prevent GSK-3-mediated phosphorylation o f c-MYC.
21
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Furthermore, coexpression o f c-MYC with KRAS in the melanocytes resulted in an
increased rate of proliferation and transformation comparable to the rate of
proliferation and transformation o f V12-NRAS alone.

Materials and Methods
Isolation of primary melanocytes and melanoma cells.
Melanocytes were isolated from 3.5 day postnatal Ink4a/Arf-null mice (15) by
separating the dorsal lateral skin from the underlying muscular layers. The skin was
washed in PBS, transferred to 0.25% trypsin, and digested overnight at 4 °C. The
epidermal and dermal layers were then separated and placed in 0.02% EDTA in PBS.
Single cells were obtained by mincing the tissue with a razor blade. After
centrifugation for 10 min at 1000 x g, the cells were plated in 100-mm culture dishes
at 37 °C with 5% CO 2 in Melanocyte Growth Medium (MGM; Clonetics, San Diego,
CA) supplemented with 5% FBS and I* penicillin/streptomycin (Invitrogen). The
cells were incubated for 14 days and the FBS was excluded from the medium after
the first two days to prevent the growth of keratinocytes and fibroblasts. The medium
was changed every two days and the supernatant was stored at -20 °C as conditioned
medium (CM). After 14 days, the cells were treated with 0.05% trypsin, split 1:3,
and grown in 1/3 CM and 2/3 MGM for 2 weeks. The cells were maintained in
MGM with 10% FBS. To obtain a pure melanocyte culture, 6.5 x 105 cells were
serially diluted across and down a 96-well plate to obtain single cell clones. Single
cells were identified in wells A8, B7, D6, E5, F4, H4, and H3. These clones were
expanded and the cells from well D6 appeared to be pure melanocytes. To ensure
22
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that the cells were of melanocyte origin, tyrosinase expression was detected within
the cells immunohistochemically (see below). Mouse melanoma cells were
established in culture from tumors that developed in Ink4a/Arf-I-,tyrosinase HRAS
mice (Jackson Labs, Bar Harbor, ME) (4).
Cell culture.
Melanocyte/melanoma cultures were maintained in 254 medium containing
human melanocyte growth supplement (HMGS) (Cascade Biologies, Portland, OR),
10% FBS, and 50 jag/ml gentamicin at 37 °C with 5% CO2 . Melan-A cells were
maintained in MEM (Invitrogen, Carlsbad, CA) containing 5% FBS, 5 mM NaHCOs,
25 pM p-mercaptoethanol, 200 nM 12-0-tetradecanoylphorbol-13-acetate (TPA;
Sigma, St. Louis, MO), 1* non-essential amino acids (Invitrogen), lx sodium
pyruvate (Invitrogen), and 1x penicillin/streptomycin (Invitrogen) at 37 °C with 5%
CO2 . DF-1 cells were grown in DMEM-high glucose supplemented with 10% FBS
and lx penicillin/streptomycin at 39 °C with 5% CO 2 . Melanocytes were incubated
with 20 mM LiCL or KC1 for 30 min where indicated.
Immunohistochemistrv.
To detect tyrosinase expression, melanocytes were cultured on Lab-Tek
Chamber Slides (Nalge Nunc International, Rochester, NY) until confluent and then
fixed with 100% methanol for 10 min at 4 °C. The cells were permeabilized with
Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) for 5 min at room
temperature (r.t.), blocked in 10% goat serum, and then incubated in rabbit anti-PEP7
antibody (V. Hearing, NIH, Bethesda, MD), which recognizes the carboxyl terminus
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of tyrosinase, diluted 1:20 in TBS-T (16). After washing three times in TBS-T,
Oregon Green 488-conjugated anti-rabbit secondary antibody (Molecular Probes,
Eugene, OR) in 2% goat serum diluted 1:50 in TBS-T was added to the sections for
30 min at r.t. in the dark. The slides were washed three times in TBS-T and stained
sections were cover slipped with anti-fade Gel/Mount aqueous mounting medium.
The signal was detected immunofluorescently using a Zeiss confocal microscope.
Microarrav data generation and analysis.
Total RNA was isolated from mouse tissue and cell lines using TRIzol reagent
(Invitrogen) according to the manufacturer’s specifications. RNA was purified by
precipitation with 7.0 M LiCl (Ambion, Austin TX), and concentrated by precipitation
with 3.0 M sodium acetate (Ambion). Coming GAPS2 microarray slides (Lot
02705000B, Coming NY) spotted with 15,361 cDNA clones from the NIA Mouse
15K clone set (National Institute on Aging, Baltimore, MD) were fabricated at the
Van Andel Research Institute, and microarray experiments were performed as
follows. Briefly, 50 pg of total RNA and an equal quantity of mouse embryo
reference RNA were primed with oligo d(T)2 oVN and reverse transcribed using
Superscript II (Invitrogen) in the presence of Cy5-dCTP and Cy3-dCTP (Perkin
Elmer, Boston MA). After direct labeling, template RNA was degraded using RNAse
One (Promega, Madison, WI) and purified using a PCR purification kit (Qiagen,
Valencia, CA). The target was concentrated by vacuum centrifugation, combined
with hybridization buffer and hybridized to a microarray slide for 19 h at 50 °C. The
slides were then washed in buffers of lx SSC with 0.1% SDS, 0.2* SSC with 0.1%
SDS, 0.2* SSC, and 0.1* SSC (Ambion), immediately dried, and scanned at 532 nm
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and 635 nm in an Agilent Microarray Scanner (Agilent Technologies, Palo Alto, CA).
Images were analyzed using Genepix Pro 5.0 (Axon, Union City, CA). Prior to
statistical analysis, spots with signal lower than three times the standard deviation of
the global array background in either channel were excluded. Clustering analysis was
performed using the SAS software version 9.1 in which euclidean distances and
average linkage clustering were used to generate the dendrogram. Prior to clustering,
missing values were imputed using the Multiple Imputation (PROC MI) method (17).
The gene expression data described in this manuscript have been deposited in NCBIs
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number GSE6194 (18).
Vector constructs.
The RCASBP(M2C)797-8 retroviral vector has been described (19). The
RCASBP(A)M7C virus (20), the RCASBP(A>tKTvirus, which encodes the activated
form of AKT designated AKT-Myr A ll-60 with a C-terminal HA tag, and
pENTR3C-TRE-K/L4iS', which contains the mutant G12V activated form of human
KRAS4B with an N-terminal FLAG epitope tag, have been described (21). The
amphotropic RCASBP(M2C)797-8 vector was converted into a Gateway™
destination vector, RCASBP(M)-DV, using the Gateway™ Vector Conversion
Reagent System (Invitrogen). RCASBP(M2C)797-8 was digested with Clal, filled-in
with Klenow to generate blunt ends, ligated to 50 ng of Reading Frame Cassette C .l,
transformed into DB3.1 Competent Cells (Invitrogen), and plated on agar plates
containing 100 pg/ml ampicillin and 30 pg/ml chloramphenicol. Orientation o f the
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Reading Frame Cassette was determined by Sail digest. Human c-MYC cDNA was
PCR-amplified from the RCASBP(A)M7C virus, cloned into the pCR8/GW/TOPO
TA cloning vector (Invitrogen), and sequence verified. pENTR3C-TRE-£&4>S' was
digested with Xhol and Xbal, and the 676-bp KRAS fragment was gel isolated and
ligated into pENTR3C digested with Sail and Xbal to generate pENTR3C-j£&4«S'.
RCASBP(A)<4XT was digested with Kpnl and Sail and the 1.5-kb fragment was gel
isolated and ligated into pENTR3C digested with Kpnl and Xhol to generate
pENTR3C-ylKX. Wild-type human NRAS cDNA was cloned from the M14-Mel
human melanoma cell line by RT-PCR into the pCR8/GW/TOPO TA cloning vector
(Invitrogen) and sequence verified. The QuickChange site-directed mutagenesis kit
(Stratagene, Cedar Creek, TX) was used to generate G12V and Q61RNRAS mutants.
RCASBP(M) expression clones were generated by mixing 150 ng of either pCR8MYC, pENTR3C-KRAS(G12V), pENTR3C-/4AT, pCR8-NRAS(G12V), or pCR8NRAS(Q61R) with 150 ng of the RCASBP(M)-DV in the presence o f the LR Clonase
Enzyme Mix per the manufacturer’s specifications (Invitrogen). LR reactions were
performed for 2 h at room temperature and 1 pi was transformed into 50 pi TOP 10One Shot Competent Cells (Invitrogen). Transformations were plated on agar plates
containing 100 pg/ml ampicillin. Primer sequences are available upon request.
Virus propagation.
Virus propagation was initiated by calcium phosphate transfection o f plasmid
DNA that contained the retroviral vector in proviral form as previously described
(21).
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Viral infections.
Melanocytes were seeded in 6-well cluster dishes at a density o f 5 x 104
cells/well 16 h prior to infection. Viral infections were performed as previously
described (21).
Cell lvsis and immunoprecipitation.
Infected melanocytes were lysed in either SDS-lysis buffer (50 mM Tris-HCl
pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol) or Myc lysis
buffer (0.1% Triton-X-100 in PBS) as indicated. Protein concentrations were
determined using the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA). For
immunoprecipitations, infected melanocytes were lysed in RIPA buffer (150 mM
NaCl, 0.5% deoxycholate, 0.1% SDS, 1% IGEPAL, 150 mM Tris-HCl, pH 8.0)
containing protease inhibitors (complete tablets, Roche, Indianapolis, IN). After
centrifugation at 16,000 x g for 10 min at 4 °C, 0.5 ml was transferred to a new tube
and incubated with 1 pg of anti-myc goat polyclonal IgG (789-G; Santa Cruz
Biotechnology, Santa Cruz, CA). After incubation for 2 h at 4 °C, 50 pi rabbit anti
goat IgG conjugated agarose beads (Sigma) were added and incubated overnight at 4
°C with constant agitation. Immune precipitates were washed three times in 1 ml of
cold RIPA buffer and resuspended in 50 pi SDS-lysis buffer. The samples were
resolved on either 10%, 14%, or 4-20% Tris-glycine SDS polyacrylamide gels
(Invitrogen), transferred to nitrocellulose, and incubated for 1 h at room temperature
in TBS-T (0.05% Tween-20 in Tris-buffered saline) blocking solution (5% non-fat
dry milk).
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Western blotting.
Blots were immunostained for NRAS and KRAS using a mouse monoclonal
anti-RAS antibody (RAS10; Upstate, Lake Placid, NY) at a 1:2000 dilution; for total
Myc using a mouse monoclonal anti-c-Myc antibody (9E10; Covance, Berkley, CA
or C-33; Santa Cruz Biotechnology) at a 1:250 dilution; for phospho T58 Myc using a
rabbit polyclonal anti-phospho-T58-Myc antibody (Abeam, Cambridge, MA) at a
1:1000 dilution; for AKT using a mouse monoclonal antibody to the HA epitope
(HA.l 1; Covance) at a 1:1000 dilution; for phospho ERK using a mouse monoclonal
anti-phospho-p44/42 MAPK (Thr202/Tyr204)

antibody (E10; Cell Signaling,

Beverly, MA) at a 1:2000 dilution; for total ERK using a rabbit polyclonal antip44/42 MAPK antibody (Cell Signaling) at a 1:1000 dilution; for tubulin using a
mouse monoclonal anti-a-tubulin (DM 1A; Sigma) at a 1:1000 dilution; and for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using a mouse monoclonal
anti-GAPDH antibody (Chemicon, Temecula, CA) at a 1:1000 dilution.

All

antibodies were diluted in blocking solution. Western blots were incubated in the
primary antibody overnight at 4 °C, washed in TBS-T, and then incubated with either
an anti-mouse or anti-rabbit IgG-HRP secondary antibody, as appropriate, diluted
1:2000 (Amersham, Piscataway, NJ) for 1 h at room temperature. The blots were
washed in TBS-T, incubated with ECL solutions per the manufacturer’s
specifications (Amersham), and exposed to film.
Growth in soft agar.
To assess anchorage-independent growth, 1.5 x 105 cells were suspended in
0.55% Difco agar noble (Becton Dickinson, Sparks, MD) in MGM/10% FBS and
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layered over pre-solidified 0.65% Difco Noble Agar in MGM/10% FBS per well of a
6-well dish. Each cell line was assayed in triplicate.
Cell proliferation studies.
Each cell line was seeded into 24 wells of a 96-well dish at a density of 5,000
cells/well. The cells were cultured and assayed for proliferation in triplicate at the
times indicated using the CellTiter 96® AQue0us One Solution Cell Proliferation Assay
(Promega) according to the manufacturer’s specifications.
In vivo studies.
Four-week-old female athymic nude mice were injected subcutaneously with
1 x 107 cells/mouse in 100 pi Hanks' balanced salt solution. Tumor size was
evaluated by caliper measurements, and tumor volume was calculated by
length x width x depth. All experiments were performed in compliance with the
guiding principles of the Guide fo r the Care and Use o f Laboratory Animals
(available at http://www.nap.edu/books/0309053773/html/) and were approved by the
VARIIACUC prior to experimentation.
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Results
Ink4a/Arf-deficient melanocytes are immortal in culture.
To study the role o f different oncogenes in melanoma formation, we generated
mouse melanocyte cell lines from Ink4a/Arf-deficient mice (15). We established a
pure melanocyte culture (lab designation D6-MEL) and confirmed the melanocyte
origin o f the cells by immunohistochemical staining for tyrosinase expression (16)
(data not shown).

It has been shown that ^//-deficiency confers immortality on

fibroblasts (22) whereas Ink4a-deficiency confers immortality on melanocytes (23).
Similarly, we observed that melanocytes isolated from

//-deficient mice

proliferated continuously and never experienced a detectable senescence crisis even
after 30 population doublings, suggesting they are immortal in culture. To ensure that
these cells were non-transformed, they were assayed for colony formation in soft agar
as well as for tumor formation in nude mice. These cultures yielded no cells that were
capable of anchorage-independent growth in soft agar and they were unable to
produce tumors in nude mice (Table 1), consistent with immortality but not
transformation.
Previous studies have demonstrated that cell lines isolated from a common
tissue tend to have consistent similarities in gene expression patterns (24). Therefore,
to further validate the melanocyte origin of the D6-MEL cells and to justify the use of
this cell line for studying melanomagenesis, we compared the gene expression profile
of the D6-MEL cell line to the gene expression profiles of several other tissues and
7/j&4aZ4//-deficient cell lines (Figure 1).

In this analysis, the D6-MEL cell line
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clusters near another melanocyte cell line, Melan-A (25), indicating that these cells
have similar patterns of gene expression. As such, this data suggests these cells were
likely derived from a common tissue type. In contrast, D6-MEL and Melan-A have
distinct gene expression patterns from Ink4a/Arf-deficient fibroblast cell lines (3T3,
YA-MEF), lymphoblast cells (VA-475), and a variety of other tissue types. Included
in this plot is data generated from two derivatives of the D6-MEL cell line (NRASMEL and KRAS-MEL) as well as a mouse melanoma cell line established from Ink4a
^4r/-/-;tyrosinase V12-HRAS mice (HRAS-MEL). The melanocytes expressing
Table 1. Tumorigenicity of Ink4a/A tf-/- melanocytes expressing different
combinations o f oncogenes.
......

Cells/gene(s)

< »'

Soft-agar growth

D6-MEL

M

Tumors in nude mice

No

0/8

V12-NRAS

Yes

8/8

V12-KRAS

Yes

4/8

AKT

No

0/8

MYC

No

0/8

MYC + AKT

Yes

0/8

V12-KRAS + AKT

Yes

8/8

V12-KRAS + MYC

Yes

8/8

V12-KRAS + MYC + AKT

Yes

8/8

Tyrosinase-V12-HRAS

Yes

8/8

M14-MEL4

Yes

8/8

-

‘D6-MEL cells were infected with viruses containing the genes indicated.
2Cells (1.5 x 105 cells/well) were resuspended in 0.55% Noble agar in growth medium and layered
over presolidified 0.65% agar in a 6-well plate. After eight weeks, colony formation was
assessed.
3Athymic nude mice (n = 8) were injected subcutaneously with 1 x 107 cells/mouse o f each cell
line and monitored for tumor formation for 12 weeks.
4M14-MEL human melanoma cells were used as a positive control.
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KRAS show the highest degree of similarity to the D6-MEL and Melan-A cell lines.
Taken together, analysis of the gene expression patterns supports the melanocyte
origin of the D6-MEL cell line.
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Figure 1. Gene expression-based evaluation of the melanocytic origin of the D6-MEL cell
line. RNA was isolated from the indicated cell lines and tissues and applied to in-house generated
cDNA microarrays. Dendrograms reflective o f the overall similarities and differences o f the cell
line and tissue gene expression patterns were generated from about 6000 o f the best measured and
variable features using average-linkage hierarchical clustering (see Materials and Methods). In the
dendrogram shown, a shorter arm indicates higher similarity while a longer arm indicates lower
similarity. All o f the cell lines analyzed are Ink4a/Arf-deficient. The samples used are as follows:
VA-MEF, mouse embryonic fibroblasts; 3T3, NIH 3T3 fibroblasts; HRAS-MEL, melanoma cells
isolated from an /«WaZ4^/-;tyrosinase-HRAS mouse; NRAS-MEL, D6-MEL melanocytes
expressing V12-NRAS; VA-475, lymphoma cells isolated from Ink4a/Arf-deficient mice; MelanA, a reported nontransformed melanocyte cell line; KRAS-MEL, D6-MEL melanocytes
expressing V12-KRAS; D6-MEL, melanocytes isolated from an Ink4a/Arf-deficient mouse and
established as a single cell clone; kidney, heart, lung, and liver represent samples isolated from
normal mouse tissue.
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RAS/MAPK activation induces anchorage-independent growth of melanocytes in
vitro.
The RAS/MAPK signaling pathway is activated in the vast majority of
characterized malignant melanomas.

Interestingly, NRAS mutations are common

while KRAS and HRAS mutations are rarely detected in melanoma (2). To determine
the efficiency of melanocyte transformation by different isoforms of RAS,
melanocytes were infected with retroviral vectors expressing either V12-NRAS or
V12-KRAS. Although Q61R-NRAS is more common in melanoma and similar
results were obtained with this mutant (data not shown), the V12 mutant was used in
these studies such that a direct comparison could be made between the transforming
capabilities of different RAS isoforms harboring the same mutation. Introduction of
either VI2-NRAS or V12-KRAS resulted in a significant increase in the total amount
of RAS protein compared with uninfected melanocytes, as assessed using a pan-RAS
antibody by Western blot (Figure 2a).
The ability of the mutant RAS isoforms to induce anchorage-independent
growth of melanocytes was initially assayed in vitro by colony formation in soft agar.
Whereas the parental, uninfected melanocytes were unable to grow in soft agar,
melanocytes expressing activated VI 2-NRAS formed numerous colonies in soft agar,
demonstrating that NRAS activation in melanocytes results in anchorage-independent
growth, a characteristic of transformed cells. Although melanocytes expressing V I2KRAS formed colonies in soft agar, they were smaller and significantly fewer in
number than melanocytes expressing VI 2-NRAS (Table 1).
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NRAS activation in melanocytes is potently tumorigenic in vivo.
While anchorage-independent growth suggests that activated NRAS and
KRAS are transforming in melanocytes, a more stringent assay o f tumorigenic
potential is the ability to form tumors in vivo. To determine the relative efficiency of
tumor formation in vivo by different RAS isoforms, melanocytes expressing either
V12-N, H, or KRAS were injected subcutaneously into nude mice. Whereas the mice
injected with the parental, uninfected melanocytes did not produce tumors, all of the
mice injected with melanocytes expressing V12-NRAS developed tumors (Table 1,
Figure 3). These tumors reached 200 mm3 within five weeks. All of the mice injected
with melanocytes expressing activated HRAS also developed tumors, but the growth
of these tumors was slightly delayed compared with the NRAS tumors, taking an
additional two weeks to reach 200 mm3. In contrast, only four of eight mice injected
with melanocytes expressing activated KRAS developed tumors (Table 1, Figure 3),
and these tumors progressed significantly more slowly than tumors expressing either
activated NRAS or HRAS. The KRAS-expressing tumors reached a volume o f 200
mm five weeks later than tumors expressing activated NRAS (Figure 3). The slightly
slower tumor growth observed with melanocytes expressing V12-HRAS compared
with melanocytes expressing VI 2-NRAS is most likely due to differences in RAS
expression levels between the virally infected NRAS cells and the cells from the
Ink4a/Arf-n\x\[-TyrosmasQ-HRAS mice where expression of HRAS is driven from the
tyrosinase promoter (4). NRAS and KRAS expression was similar in the D6-MEL
cells (Figure 2a).
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NRAS and KRAS both activate the classical MAPK pathway in melanocytes.
In further support of the in vitro and in vivo growth differences between the
N-, H- and KRAS-expressing melanocytes, these cell lines also have differences in
their corresponding gene expression patterns (Figure 1). Based on gene expression
data, the melanocytes expressing activated KRAS show a high degree of similarity to
the D6-MEL and Melan-A cell lines. In contrast, the H- and NRAS-transformed
melanocytes show lesser similarity to the D6-MEL and Melan-A melanocytes and
have the greatest degree of similarity to the highly transformed and highly
proliferative VA-475 lymphoma cells. These data suggest that the altered patterns of
gene expression in the N- and KRAS-expressing cell lines may be the result of
differential activation of RAS signaling pathways and/or differences in overall cell
proliferation.
To determine if the difference in in vivo tumorigenicity between KRAS and
NRAS is due to differential activation of the classical MAPK signaling pathway (i.e.,
RAF/MEK/ERK; Figure 2b), cell lysates were collected from D6-MEL cells
expressing either V12-NRAS or V12-KRAS. Expression of either activated NRAS
or KRAS strongly activated ERK in these cells (Figure 2a). Since ERK
phosphorylation mediated by both RAS isoforms is robust, the greater in vivo
tumorigenic potential of NRAS appears not to be due to differential ERK activation.
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Figure 2. Proposed RAS signaling pathways, (a) Expression o f RAS and ERK activation in D6MEL cells. Cell lysates from uninfected D6-MEL melanocytes (-) or cells infected with
retroviruses containing either V12-NRAS or V12-KRAS (+) were collected in SDS lysis buffer,
separated on a 4-20% gradient gel and immunoblotted for total RAS expression (a-RAS), activated
phosphorylated ERK p44/42 (a-pERKl/2), total ERK p44/42 expression (a-Total ERK1/2), and atubulin. (b) Schematic representation o f RAS signaling pathways and their effect on Myc activity.
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Figure 3. In vivo tumor formation. Nude mice were injected subcutaneously with 107 uninfected
melanocytes (D6-MEL) or melanocytes expressing the indicated genes. Tumor volume was
determined by caliper measurement on the days indicated (data are represented as mean ± SEM; n =
8 ).
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NR A S. but not KRAS, increases the rate of proliferation of melanocytes and prevents
GSK3-mediated phosphorylation o f Mvc.
In culturing the melanocytes expressing V12-NRAS or KRAS, we observed
that cells expressing V12-NRAS grew at a faster rate than either uninfected
melanocytes or melanocytes expressing V12-KRAS. This observation was confirmed
by measurement o f the in vitro proliferation rates o f the cells. Expression of V I2NRAS significantly increased the proliferation rate of the melanocytes (Figure 4). In
contrast, the V12-KRAS melanocytes proliferated at the same rate as the uninfected
melanocytes until day 8, at which point their growth was significantly reduced
compared with that of all the other cell lines (Figure 4). To determine the mechanism
responsible for the disparity in growth and tumorigenicity, differences in downstream
RAS effectors known to play a role in proliferation were evaluated.
The c-Myc protein plays a role in multiple cellular processes, including
proliferation, and is a downstream target of RAS signaling (26). We assessed
endogenous c-Myc expression in cell lysates from uninfected melanocytes, and
melanocytes expressing either V12-NRAS or V12-KRAS. When these samples were
separated on a gradient polyacrylamide gel, a differential c-Myc banding pattern was
observed. We suspected that the higher-molecular-weight bands were posttranslationally modified forms of Myc, since Myc has been reported to be
phosphorylated by ERK at serine 62 (S62) and by glycogen synthase kinase-3
(GSK3) at threonine 58 (T58) (27). These two phosphorylation sites exert opposing
control on c-Myc stability; whereas S62 phosphorylation stabilizes c-Myc, T58
phosphorylation promotes S62 dephosphorylation and ubiquitin-mediated proteasome
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degradation. Myc is normally turned over rapidly in cells, but RAS signaling
stabilizes Myc by inducing phosphorylation o f S62 through the MAPK/ERK pathway
(26)

and

by

inhibiting phosphorylation

of Myc

at T58

by

GSK3

via

phosphatidylinositol 3-kinase (PI3K) signaling (28) (Figure 2b).

o
2

1.5

KRAS+MYC

Q 0.5

MYC
D6-MEL
KRAS

0

2

4

6

10

8

12

14

16

Time in Culture (days)
Figure 4. In vitro proliferation of melanocytes expressing different genes. Uninfected
melanocytes (D6-MEL) or melanocytes infected with retroviruses containing V12-NRAS, V I2KRAS, MYC, or V12-KRAS coexpressed with MYC were seeded in microtiter wells and assayed
at the indicated time points. Viable cells were quantitated using the CellTiter 96® AQueous One
Solution Cell Proliferation Assay by optical density readings at 490 nm (data are represented as
mean ± SEM; n = 3).

Consistent with

observations

in

other

cell

types,

the

S62

singly

phosphorylated protein was more pronounced in the NRAS- and KRAS-expressing
melanocytes than in uninfected melanocytes (Figure 5a, 56-kDa band). Flowever,
whereas the uninfected melanocytes and the KRAS-expressing melanocytes both
showed T58/S62 dual phosphorylation (Figure 5a, 51-kDa band), NRAS-expressing
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cells did not, suggesting that NRAS more effectively prevents GSK3-mediated
phosphorylation of Myc at T58 than does KRAS in these cells.
To further verify the differential phosphorylation of Myc and to analyze the
contribution of the PI3K/AKT/GSK3 pathway to Myc regulation, uninfected
melanocytes and melanocytes expressing either V12-NRAS or V12-KRAS were
incubated in the presence or absence of lithium to inhibit GSK3-mediated
phosphorylation of Myc at T58 (29, 30). Following treatment, endogenous Myc
protein was immunoprecipitated and phosphorylation was detected using a T58
phospho-specific Myc antibody. Prominent T58 Myc bands were detected in lysates
from uninfected melanocytes and melanocytes expressing V12-KRAS, but not from
those expressing V12-NRAS (Figure 5b, top panel). Upon inhibition of GSK3
activity by lithium treatment, T58 phosphorylation o f Myc was no longer detectable
(Figure 5B, top panel). Effective inhibition o f GSK3 by lithium was verified by
analysis of the same cell lysates prior to immunoprecipitation of Myc using a
phospho-specific GSK3 antibody (Figure 5b). Inhibition o f GSK3 correlates with an
increase in the level of phosphorylated GSK3. These results suggest that
phosphorylation of Myc at T58 is mediated by GSK3 in melanocytes, and further
demonstrate that V12-NRAS effectively prevents GSK3-mediated phosphorylation of
Myc whereas V12-KRAS does not.
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Figure 5. RAS-mediated regulation o f c-Myc phosphorylation, (a) Cell lysates from uninfected
melanocytes (-) or melanocytes infected with retroviruses containing V12-NRAS or V12-KRAS
(+) were collected in Myc lysis buffer, separated on a 4-20% polyacrylamide tris-glycine gradient
gel, and immunoblotted for endogenous Myc expression using an anti-Myc monoclonal antibody
(9E10; a-MYC). The S62-Myc band (56 kDa) is predicted to be larger than the doubly
phosphorylated S62/T58-Myc band (51 kDa) due to glycosylation o f T58 in the absence o f
phosphorylation (30). The blot was re-probed for GAPDH to ensure equal loading (a-GAPDH).
(b) Uninfected melanocytes (£) or melanocytes infected with retroviruses containing V12-NRAS
(NRAS! or V12-KRAS (KRAS) were treated with either 20 mM LiCI or KC1 (as a control) for 30
min. After treatment, cell lysates were collected in RIPA buffer and phosphorylated GSK3 (apGSK3) and tubulin (a-Tubulin) were detected from whole cell lysates, while T58 Myc
phosphorylation (a-pT58) and total Myc (9E10; a-MYC) were detected from c-Myc
immunoprecipitates with the antibodies indicated.

Coexpression of KRAS and either MYC or AKT increases the tumorigenicitv of
melanocytes.
To determine if coexpression o f KRAS with either AKT, MYC, or both AKT
and MYC would result in tumorigenicity comparable to that induced by expression of
NRAS alone, melanocytes expressing MYC or AK T were infected with retroviruses
containing V12-KRAS to generate melanocytes expressing KRAS and MYC, KRAS
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and AKT, or KRAS, AKT, and MYC. Melanocytes expressing AK T alone, MYC alone,
and the combination of AK T and MYC in the absence o f KRAS were generated as
controls. Expression of individual genes was confirmed by Western blot (Figure 6).
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Figure 6. Expression o f KRAS, A K T and M YC in melanocytes. KRAS, AKT, and/or c-MYC were
stably introduced into D6 melanocytes by retroviral infection in the combinations indicated (+).
Expression o f each gene was assayed by immunoblotting cell lysates collected in SDS lysis buffer
and separated on 10% (MYC and AKT) or 14% (RAS) polyacrylamide gels with antibodies to cMYC (C-33; a-MYC), the HA epitope tag on AKT (H A .ll; a-AKT-HA), RAS (RAS10; a-RAS),
and tubulin (DM 1A; a-tubulin). * Indicates a nonspecific band.

Expression of either MYC or AK T alone is not sufficient to transform the melanocytes
even in the context o f Ink4a/Arf deficiency. Neither soft agar colonies nor in vivo
tumors formed from melanocytes expressing only MYC or AK T (Table 1, Figure 7).
However, coexpression o f KRAS with either AK T or, more dramatically, MYC
resulted in potent transformation. Whereas melanocytes expressing V12-KRAS alone
only formed tumors in half of the injected mice with a long latency, tumors were
detected in all of the mice injected with melanocytes coexpressing KRAS and AKT
(Table 1). The kinetics of tumor growth outpaced that of KRAS-only tumors, but still
lagged behind NRAS tumors (Figure 7). Coexpression of KRAS and MYC was even
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more potently tumorigenic than KRAS with AKT. Tumors developed in all mice
injected with KRAS- and MFC-expressing melanocytes (Table 1); the tumor growth
kinetics were indistinguishable from the rate of NRAS-induced tumors. Additional
expression of AK T did not significantly enhance the tumorigenicity of KRAS- and
MYC-expressing melanocytes (Figure 7). These results further support the idea that
either MYC or AKT is capable of cooperating with KRAS in this system.
Furthermore, in the absence of V12-KRAS expression, coexpression of MYC and
AKT resulted in the formation of soft agar colonies but not in vivo tumors (Table 1,
Figure 7). These results further illustrate the importance of a RAS signal in this
context.
1200
1000

NRAS
KRAS + AKT + MYC
KRAS + MYC

800
O

600

m

■KRAS + AKT-

400
200

MYC
AKT

10

20

30

40

50

60

70

80

90

100

Time (days)
Figure 7. In vivo tumor formation. Nude mice were injected subcutaneously with 107
uninfected melanocytes (D6-MEL) or melanocytes expressing the indicated genes. Tumor volume
(represented as mean ± SEM; n = 8) was determined by caliper measurement on the days indicated.
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The proliferation rate of KRAS-expressing melanocytes is increased by MYC
expression.
To further explore the mechanisms that underlie the differences in
tumorigenic potential of the RAS isoforms, and to further characterize how MYC
coexpression

increases the tumorigenicity

of V12-KRAS

melanocytes, the

proliferation rates of melanocytes expressing V12-NRAS, V12-KRAS, and MYC, as
well as the combination of V12-KRAS and MYC, were measured. While V12-KRAS
or MYC expression alone did not affect the cellular proliferation rate, coexpression of
MYC with V12-KRAS increased the proliferation rate of the melanocytes to a rate
similar to that observed by V12-NRAS alone (Figure 4). This indicates that MYC
expression cooperates with V12-KRAS by increasing the rate of cellular
proliferation.

Discussion
Using a genetically defined system, we demonstrate that the combination of
V12-NRAS expression and Ink4a/Arf loss is potently tumorigenic in melanocytes,
whereas transformation by V12-KRAS requires the expression of a cooperating
oncogene. V12-NRAS expression alone significantly increases the proliferation of
//-deficient melanocytes. In contrast, V12-KRAS expression does not
enhance cell proliferation, but rather induces growth arrest at higher cell densities.
While tumors did develop in half of the mice injected with V12-KRAS-expressing
Ink4a/Arf-deficiQnt melanocytes, the long latency and incomplete penetrance of
tumor formation in these mice suggests that additional genetic changes were acquired
over time.
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It has been established that RAS and MYC can cooperate in the
transformation of rodent fibroblast and mammary epithelial cells (13, 14). However,
the mechanism responsible for this cooperation has not been elucidated in
melanocytes. Analysis of downstream RAS effector pathways revealed that while
both V12-NRAS and V12-KRAS efficiently activate the classical MAPK pathway in
melanocytes, only V12-NRAS effectively prevents GSK3-mediated phosphorylation
of Myc via PI3K/AKT, which results in enhanced activity of endogenous Myc protein
in these cells. These results are in agreement with observations in fibroblasts where
HRAS more effectively activates PI3K than does KRAS (31). Since both HRAS and
NRAS co-localize to lipid rafts, whereas KRAS is excluded from lipid rafts and
localizes to the disordered plasma membrane (7), the more potent activation of
PI3K/AKT by NRAS and HRAS may be due to differential membrane localization
and therefore access to a defined subset of downstream effector proteins.
Alternatively, recruitment of PI3K to distinct domains (e.g., lipid rafts) within the
plasma membrane may result in activation that is more efficient than that of KRAS.
The importance of the PI3K/AKT/MYC pathway in melanoma genesis was
further illustrated by the combination of V12-KRAS with either AKT or MYC, which
results in transformation efficiencies similar to that o f V12-NRAS alone. Inactivating
PTEN mutations, which result in enhanced AKT activity, appear to be mutually
exclusive with NRAS mutations in human melanoma tissues and cell lines,
suggesting overlapping redundant functions. Furthermore, half of melanomas with
BRAF mutations, which activate downstream MAPK signaling but not PI3K/AKT
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signaling, also harbor PTEN mutations (32). Concurrent BRAF/PTEN mutations
appear to function like an NRAS mutation in melanomagenesis.
While we have observed that NRAS is the most potent RAS protooncogene in
melanocytes, HRAS and KRAS mutations are clearly selected for in tumors of
different cellular origins. The differences that we and others have observed in the
ability of the RAS proteins to activate different effector molecules may explain the
selection pressure for specific RAS mutations in certain human tumors. The presence
of additional mutations in other genes most likely contributes to this selection
pressure, and the multistep process of oncogenesis varies significantly between cell
types. For example, in colorectal cancer loss o f the adenomatous polyposis coli
(APC) gene is an early event that results in increased levels of |3-catenin and
subsequent increases in MYC gene expression (33). Since loss of APC typically
precedes activation of KRAS in colorectal cancer progression, this may explain the
selection pressure for KRAS mutation in those cells.
Our results demonstrate the importance of NRAS-mediated activation of both
MAPK and PI3K/AKT/MYC signaling in melanoma genesis and identify distinct
differences between the signaling capabilities of NRAS and KRAS in melanocytes.
These differences offer a rationale explanation for the greater occurrence of NRAS
mutations relative to KRAS mutations in melanoma. In addition, the relative
resistance to MEK inhibition of melanomas harboring NRAS mutations (34) suggests
that these tumors may be ideal candidates for combination therapies that also target
the PI3K/AKT/MYC pathway.
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CHAPTER III
MALIGNANT TRANFORMATION OF MELANOCYTES BY
OVEREXPRESSION OF p90 RIBOSOMAL S6 KINASE
This work has been submitted for publication.
Abstract
While many genetic alterations have been identified in melanoma, the relevant
molecular events that contribute to melanocyte tumorogenesis and metastasis are
poorly understood. Most melanomas harbor activating mutations in NRAS or BRAF
conferring constitutive activation of MAPK signaling that results in downstream
activation of many effectors including p90 Ribosomal S6 Kinase (RSK). Although
RSK promotes survival through inactivation of the pro-apoptotic protein BAD and
also regulates cell cycle progression, it has not been implicated in melanomagenesis.
We observed high levels of RSK activation in all human melanoma cell lines
examined as well as overexpression in several of these cell lines. Expression of wild
type and a constitutively active form of RSK enhanced mouse melanocyte
proliferation. Using a CDKN2A deficient melanocyte cell line we show that
overexpression of constitutively active or wild-type RSK can transform mouse
melanocytes in vitro and in vivo in this context. However, RSK expressing tumors
exhibited delayed tumor growth compared with NRAS expressing tumors suggestive
of secondary genetic events required for progression. Upon investigation, high level
intrachromosomal gene amplification of Met, a growth factor receptor tyrosine kinase
implicated in melanoma progression, was identified in each independent RSK
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expressing tumor. MET expression is rarely detected in primary human melanoma,
but is frequently observed in advanced metastatic disease and therefore may be an
attractive therapeutic target to prevent disease progression.
Introduction
The incidence of melanoma has increased by more than 600% over the last
forty years; 59,940 new cases are expected in the United States this year (1). If
detected early, the disease is treatable; however, following metastasis it is largely
resistant to most conventional therapies and is associated with a high mortality rate
(2). Several loci mutated in familial or sporadic melanoma have been identified,
providing targets for study and potentially for therapeutic intervention (reviewed in
(3)). The CDKN2A locus has been linked to numerous cancers, including melanoma
and encodes two distinct tumor suppressor proteins:

p i 6 ^ ^ , which inhibits

CDK4/6 and cell cycle progression, and p l4 ARF a key element involved in p53
regulation (4, 5). With less frequency, mutations in tumor suppressors such as p53,
PTEN, and Rb have also been reported (3). With mutually exclusive mutations in
NRAS and BRAF, the mitogen-activated protein kinase (MAPK) signaling pathway is
constitutively activated in over 70% of sporadic malignant melanomas (6). NRAS and
BRAF mutations are frequently found in benign nevi suggestive o f an important
initiating role in melanoma genesis whereas hyperactive receptor tyrosine kinase
(RTK) signaling by the epidermal growth factor receptor (EGFR) or c-MET has been
associated with melanoma progression and metastasis (7-9). MAPK signaling
promotes survival in human melanoma cell lines as small molecule inhibitors of
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MEK induce high levels of apoptosis, whereas normal melanocytes experience a cell
cycle arrest (10-12).
The family o f 90-kDa serine/threonine ribosomal S6 kinases (RSK or p90rsk)
was among the first MAPK substrates identified. In humans, there are four separate
genes encoding the RSK isoforms (RSK1, 2, 3 and 4) and mutations in RSK-2 have
been associated with the X-linked neurodegenerative disorder Coffin-Lowry
syndrome, which is characterized by skeletal abnormalities and mental retardation
(13,14). RSK contains two distinct kinase domains: The N-terminal domain (NTD) is
responsible for phosphorylation of all known RSK substrates while the C-terminal
domain (CTD) is autoregulatory.

RSK is activated through ERK and 3-

phosphoinositide-dependent

kinase

protein

1

(PDK1)

phosphorylation

and

subsequent autophosphorylation of the NTD by the CTD (10, 11, 15). In melanoma
cell lines, RSK-1 has been shown to be the most activated isoform, but RSK-2 and
RSK-3 are present and active as well (11). Once activated, the targets o f RSK are
diverse, regulating cell cycle progression, transcription, and survival. Transcription
factors such as cAMP response element-binding (CREB), c-Fos, Myt-1, and Nuclear
factor-KB (NF-kB) have been reported as RSK targets, as well as several proteins
related to cell cycle progression and survival (16-18). RSK has been shown to
promote survival through phosphorylation and subsequent inactivation of the proapoptotic Bcl-2 family member Bad (15, 16, 19). This activity can be MAPK
independent (11, 15), but overexpression of active RAS and RAF increase Bad
phosphorylation while MEK inhibitors reduce Bad phosphorylation (15, 16, 19).
Phosphorylation o f the inactivating Ser75 residue in human Bad is dependent on
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activation of ERK and RSK in melanoma cells but not in normal melanocytes (11).
MEK inhibitors block Bad phosphorylation/inactivation and this coincides with the
onset o f melanoma cell apoptosis. Subsequent expression of constitutively active
RSK circumvents MEK inhibition, resulting in increased Bad phosphorylation and
increased survival of melanoma cells (11).
In this study, we examined the expression and activation of RSK in human
melanoma cells and found that RSK is highly activated in several melanoma cell
lines, compared with normal melanocytes. In some melanoma cell lines, RSK-1 was
overexpressed. We observed that overexpression of wild-type (wt) RSK or a
constitutively active mutant o f RSK (RSK-CAII) increases the proliferation of
melanocytes

in

vitro.

In

addition,

RSK

overexpression/activation

induces

transformation of melanocytes devoid of Ink4a/Arf, but in vivo tumor growth was
significantly delayed compared with cells expressing activated NRAS. This delay in
tumor growth in the RSK expressing cells suggested that additional genetic events
were required. Cytogenetic analysis of RSK-induced tumors revealed high-level
amplification of the RTK Met. This amplification was intrachromosomal and was
found only in tumors driven by overexpression of wild-type RSK.
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Materials and Methods
Cell culture.
Mouse melanocytes and neonatal human epidermal melanocytes (Cascade
Biologies, Portland OR) were cultured in 254 media containing HMGS, 5% FBS, and
50 pg/ml gentamicin at 37 °C with 5% CO2 . Human melanoma cell lines were
obtained

from

the

Developmental

Therapeutics

Program, National

Cancer

Institute/NIH and cultured in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented
with 5% FBS, 2 mM L-glutamine, and 50 pg/ml gentamicin at 37 °C with 5% CO2 .
Single cells were obtained from subcutaneous tumors by mincing the tissue with a
razor blade followed by incubation in 0.05% trypsin for 45 min at 37 °C. Cells were
established in culture and maintained in 254 media supplemented with 10% fetal
bovine serum. DF-1 cells were grown in DMEM-high glucose (Invitrogen)
supplemented with 10% fetal bovine serum, 100 units of penicillin per ml, and 100
pg of streptomycin per ml, and maintained at 39 °C with 5% CO2 (30, 31).
Inhibitors.
PD98059

(Cell

Signaling,

Beverly,

MA)

and

PD 184352

(Upstate

Biotechnology, Lake Placid, New York) was dissolved in DMSO, and the cells were
treated as previously described (10). Controls were treated with an equivalent volume
of DMSO.
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Immunohostochemistrv.
M14-MEL and SK-MEL-28 cells that were treated with either DMSO or
PD98059 were formalin-fixed and dehydrated through a graded alcohol series in a
Ventana Renaissance processor (Ventana Medical Systems, Tucson, AZ). The cells
were paraffin-embedded and 5 pm sections were adhered to glass slides. Following
deparaffinization and rehydration, the slides were heated in DAKO Target Retrieval
Solution (Dako, Carpinteria, CA) for 25 min for antigen retrieval. The slides were
cooled, rinsed three times in cold water and then washed once in phosphate-buffered
saline (PBS) with 0.05% Tween-20 (PBST). The slides were blocked in 1% BSA plus
5% goat serum in PBS for 30 min at room temperature. The blocking solution was
rinsed away in PBS-T and the sections were incubated with a rabbit polyclonal antip90 RSK-1 antibody (Upstate Biotechnology) diluted 1:100 in antibody dilution
buffer (Biomeda, Foster City, CA) overnight at 4°C. During this period, the sections
were covered with coverslips for even distribution o f the antibody and to prevent
excessive evaporation. After washing in PBS-T three times for 5 min each, the
sections were reacted with 1:100 dilution of Alexa-Fluor 488-conjugated goat anti
rabbit IgG antibody (Molecular Probes, Eugene, OR) and the DNA dye TO-PR03
600 nM (Molecular Probes, Inc.) to mark the nuclei in antibody dilution buffer
(Biomeda) for 1 hr at room temperature in the dark. After washing in PBS-T three
times for 15 min each, the slides were mounted with coverslips. The stained sections
were imaged on a confocal microscope and analyzed with the Image Pro-Plus v.4.1
software (Media Cybernetics, Bethesda, MD). Activation of RSK-1 was estimated
with the relative nuclear/cytoplasmic staining ratio.
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Vector constructs.
The pLPCX-RSK-IRES-GFP retroviral vectors (11), and the RCASBP(M)NRAS (Q61R) retroviral vector (20) have been described.
Virus production.
RCASBP(M)-NRAS (Q61R) viral infection was initiated by calcium
phosphate transfection o f plasmid DNA that contained the retroviral vector in
proviral form (32). In standard transfections, DF-1 cells were plated at 30%
confluency, allowed to attach (2-3 h), and 5 pg of purified plasmid DNA was
introduced using the mammalian transfection kit (Stratagene, Cedar Creek, TX) per
the manufacturer’s specifications, followed by a 5 min glycerol shock at 39 °C (15%
glycerol in the medium). Viral spread was monitored by assaying culture supernatants
for avian leukosis virus capsid protein by ELISA as previously described (33). Virus
stocks were generated from the cell supernatants. The supernatants were cleared of
cellular debris by centrifugation at 2000 * g for 10 min at 4 °C, filtered through a
0.45-pm filter, and stored in aliquots at -8 0 °C. Virus was determined to be
replication-competent by a reading of 0.200 or greater on ELISA for the viral capsid
protein (33). The pLPCX-RSK-IRES-GFP retroviral vectors were transfected into the
293-GPG helper cell line to produce VSV-G pseudotyped viral stocks and viral titers
were determined on HEK293 cells as previously described (11).
Viral infections.
Melanocytes were seeded in 254 media containing human melanocyte growth
supplement (HMGS) (Cascade Biologies, Portland, OR) and 10% FBS in 6-well
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cluster dishes at a density of 5 x 104 cells/well 16 h prior to infection at 37 °C. The
next day, the medium was removed and replaced with 1 ml of filtered viral stock in
the presence of 8 pg/ml of polybrene (Sigma, St. Louis, MO) for 6 h at 37 °C. After
the infection, the virus containing media was removed, replaced with fresh media,
and the cells were expanded. For pLPCX-RSK-IRES-GFP infections, stable
expressing cells were selected with 50 pg/ml puromycin and pooled.
Western blotting.
Melanocytes or melanoma cells were washed with PBS and 150 pi SDS-lysis
buffer was added to each well of a 6-well dish. The cell lysates were boiled for 10
min and passed through a 26-gauge needle 5 times. Following centrifugation, the
proteins were separated on a 14% Tris-glycine polyacrylamide gel, transferred to
nitrocellulose, and incubated for 1 h at room temperature in blocking solution (0.05%
Tween-20 in TBS with 5% non-fat dry milk). Blots were immunostained for NRas
using an anti-NRas monoclonal antibody (Ab-1; Oncogene, San Diego, CA) at a
1:1000 dilution; for total RSK-1 using an anti-RSK-1 monoclonal antibody (Upstate
Biotechnology); for phospho-RSK (T-573) using a rabbit polyclonal antibody (9346;
Cell Signaling) at a 1:1000 dilution; for phospho ERK using a mouse monoclonal
anti-Phospho MAPK antibody (E10; Cell Signaling) at a 1:1000 dilution; Total ERK
using a rabbit polyclonal anti-MAPK antibody (Cell Signaling) at a 1:1000 dilution;
and anti-a-tubulin (AB-1) at a 1:1000 dilution (Oncogene). All antibodies were
diluted in blocking solution. Western blots were incubated in the primary antibody
overnight at 4 °C with constant shaking and then washed three times in TBS-T wash
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buffer (0.05% Tween-20 in Tris-buffered saline). The blots were then incubated with
either an anti-mouse or anti-rabbit IgG-HRP secondary antibody diluted 1:3000
(Sigma, St. Louis, MO) for 1 h at room temperature. The blots were washed three
times in TBS-T wash buffer, incubated with ECL solutions per the manufacturer’s
specifications (Amersham, Piscataway, NJ), and exposed to film.
Growth in soft agar.
To assess anchorage-independent growth, 1.5 x 105 cells were suspended in
0.55% Difco agar noble (Becton Dickinson, Sparks, MD) in MGM/10% FBS and
layered over pre-solidified 0.65% Difco agar noble in MGM/10% FBS per well of a
6-well dish. Fresh medium was added twice per week for 4 weeks. Each cell line
was assayed in triplicate.
Cell proliferation studies.
Each cell line was seeded into 24 wells of a 96-well dish at a density of 5
x 103 cells/well. The cells were cultured and assayed for viable cell count at the
times indicated using the CellTiter 96® A Q ue0us One Solution Cell Proliferation Assay
(Promega, Madison, WI) according to the manufacturer’s specifications.
In vivo studies.
Four-week old female athymic nude (NCr nu/nu) mice were injected
subcutaneously (s.c.) on the right upper dorsal area with 1 x 107 cells/mouse in 100 pi
Hanks' balanced salt solution (HBSS). Tumor size was evaluated by caliper
measurements, and tumor volume was calculated by length x width x depth. For
histological examination, tumors were dissected, fixed in 10% neutral-buffered
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formalin overnight, embedded in paraffin blocks, and cut into thin sections. All
experiments were performed in compliance with the guiding principles of the “Care
and Use of Animals” (available at http://www.nap.edu/books/0309053773/htmlA and
were approved by the IACUC prior to experimentation.
Metaphase spreads.
Melanocytes were incubated overnight with colcemid (12ng/ml; Invitrogen) to
arrest cells in metaphase. Cells were detached by trypsin, washed twice in PBS and
then gently resuspended in 5 ml 37 °C, 75 mM KC1 for 10 min. to permeablize the
plasma membrane, and fixed in 10 ml ice cold fixative (75% methanol, 25% glacial
acetic acid).
Reverse DAPI.
Metaphase spread slides were prepared from cell cultures that were harvested
and fixed with methanokacetic acid (3:1), as described above. Slides were aged
overnight at 55 °C. Once slides were cooled to room temperature, DAPI was applied
and covered with a glass cover slip. Image acquisition was performed with a COOL1300 SpectraCube camera (Applied Spectral Imaging-ASI, Vista, CA) mounted on an
Olympus BX51 epifluorescence microscope and analyzed using FISHView software
(EXPO 4.0, ASI). Chromosomes were counted and obvious aberrations were noted
for at least 20 metaphases per slide.
Spectral karyotyping (SKY).
Metaphase spreads were prepared from cell cultures as described above and
SKY was performed according to the standard supplied protocol (ASI) on freshly
prepared metaphase

slides

to

investigate

cytogenetic

abnormalities.
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Image

acquisitions were performed using a SKY™ Spectracube™ system (ASI) with a highresolution scientific digital camera (VDS Vosskiihler GmbH) mounted on an
Olympus BX51 microscope with a custom designed optical filter (SKY-1, Chroma
Technology, Brattleboro, VT). Twenty metaphases were analyzed using the
SKYView v 1.6.2 software (ASI).
Fluorescent in situ hybridization (TISHF
FISH probes were prepared from purified BAC clones RP23-73G15 and
RP24-462C10

(Children’s

Hospital

Oakland

Research

Institute;

http://bacpac.chori.orgI and labeled with SpectrumOrange and SpectrumGreen
(Abbott Molecular Inc, Des Plaines, IL), respectively, by nick translation. These
probes were used to detect M et amplification within region 6A2 and region 6D3 as a
control, respectively. Metaphase spread slides were prepared from cell cultures that
were harvested and fixed with methanolracetic acid (3:1), as described above. The
slides were pretreated with 2X saline/sodium citrate at 37 °C for 10 min, 0.005%
pepsin at 37 °C for 4 min, and lx PBS for 5min. The slides were then placed in 1%
formaldehyde for 10 min at room temperature, washed with lx PBS for 5 min, and
dehydrated in an ethanol series (70%, 85%, and 95%) for 2 min each. Samples were
denatured in 70%

f o r m a m id e / 2 x

saline/sodium citrate at 73 °C for 5 min, washed in a

cold ethanol series (70%, 85%, 95%) for 2 min each, and air dried. FISH probes were
denatured at 73° C for 5 min before applying to each dried slide and mounted with a
glass cover slip. The slides were hybridized overnight at 37 °C, washed with 2x
saline/sodium citrate at 73° C for 2 min, and rinsed briefly in H 2 O. Slides were then
air-dried, counterstained with anti-fade 4'-6-diamidino-2-phenylindole (DAPI), and
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covered with cover slips. Image acquisition was performed with a COOL-1300
SpectraCube camera (ASI) mounted on an Olympus BX51 epifluorescence
microscope and analyzed using FISHView 4.0 software (ASI). Hybridization signals
were analyzed for at least 10 metaphases per slide.

Results
RSK is overexpressed and highly activated in human melanoma cells.
We examined RSK expression and activation in a subset of melanoma cell
lines and normal melanocytes. We observed that RSK is overexpressed and highly
activated in all of the melanoma cell lines tested compared with normal melanocytes
(Figure 1). Inhibition of MEK activity with the small molecule MEK inhibitor
PD184352 resulted in inactivation of the downstream protein kinase ERK and RSK in
these melanoma cell lines (Figure 1). Localization by subcellular fractionation
revealed that the majority of active, phosphorylated RSK was localized to the nucleus
(Figure 1). To further examine the subcellular localization of both active and inactive
RSK-1, we performed immunohistochemistry for RSK-1 on formalin-fixed, paraffinembedded cell blocks generated from M14-MEL and SK-MEL-28 cells treated with
DMSO (active RSK-1) or the MEK inhibitor PD98059 (inactive RSK-1). Consistent
with the immunoblotting results (Figure 1), a higher level of RSK-1 expression was
detected in the M14-MEL cells (mean staining intensity 118 ± 5) compared with SKMEL-28 cells (84 ± 17) (Figure 2A). Increased nuclear RSK-1 staining was detected
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in the DMSO-treated control cells compared with the PD98059-treated cells,
indicating nuclear translocalization of active RSK-1 (Figure 2A).

NHEM

MW! -

+

M14

-

3M

+

28

+ : PD184352
p-RSK
RSK-1
P-ERK1
P-ERK2

50
"ERK1&2

37

Tubulin
"cytosolic
'■■■!■

Tubulin
nuclear

Figure 1. MAPK (ERK1&2) and RSK activation in melanoma cell lines. Cells were treated with
PD184352 (+) or DMSO (-) for 72 hours. Lysates were subjected to nuclear and cytoplasmic
fractionation. Active phospho-MAPK (ERK1P and ERK2P), total MAPK (ERK1 & 2), and tubulin
immunoblots from the cytoplasmic fraction are shown. Active phospho-RSK (RSKP), total RSK-1,
and tubulin immunoblots from the nuclear fraction are shown. For comparison, the actively growing
normal human epidermal melanocytes (NHEM) were included.

RSK overexpression/activation increases the proliferation of melanocytes.
To determine the functional significance of RSK overexpression and/or
activation, we introduced wt RSK and constitutively active mutants of RSK, RSKCAI or CAII, into Ink4a/Arf-mx\\ immortalized melanocytes (20). RSK-CAI contains
an N-terminal myristoylation sequence in addition to several activating mutations
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Figure 2. Indirect immunofluorescent staining of RSK-1 in human melanoma ceils treated with
DMSO or PD98059. M14-MEL and SK-MEL-28 cells were treated with DMSO or PD98059 for 24
hrs. The cells were fixed in formalin, embedded in paraffin, and 5 pm sections were adhered to glass
slides. Following antigen retrieval, RSK-1 expression (green) was detected immunohistochemically.
Nuclei were marked by co-staining with the DNA dye T0-PR03 (red; Molecular Probes, Inc.). Mean
staining intensities calculated from six independent images for M14-MEL and SK-MEL-28 cells were
118 ± 5 and 84 ± 17, respectively. A ratio (N/C) o f the mean staining intensity within nuclear regions
to cytoplasmic staining is also shown for each image.

(T357EED, S363EDD, Y702A) (Figure 3A). RSK-CAII lacks the first 43 N-terminal
amino acids and also contains several activating mutations (T357EED, S363EDD,
Y702A) (Figure 3A).

The activity of these RSK constructs was previously

demonstrated by an in vitro kinase assay using recombinant GST-mouse Bad as a
substrate (11).

The introduction of wt RSK or constitutively active RSK in

Ink4a/Arf-null melanocytes led to an increase in RSK protein as assessed by Western
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blot (Figure 3B, left panel). Since Ras is oncogenic in melanocytes (21), the cells
were also infected with a retrovirus encoding constitutively active NRAS and
expression was confirmed by Western blot (Figure 3B, middle panel).
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Figure 3. Oncogene expression in immortal melanocytes. (A) Diagram o f p90RSK-l wild-type
(wt) and generated RSK-CAI and RSK-CAII mutants. NTKD: NH2-terminal kinase domain, CTKD:
COOH-terminal kinase domain, Myr: Myristoylation signal. (B) Western blots o f lysates from
uninfected melanocytes (Lanes 1, 5, and 7) or melanocytes infected with retroviruses containing wt
RSK (Lanes 2, 8-10), RSK-CAI (Lane 3), RSK-CAII (Lane 4), or NRAS (Q61R) (Lane 6). Lanes 9
and 10 are lysates from wt RSK expressing tumors that were established in culture and passaged for
either 3 or 10 passages, respectively. The blots were re-probed for tubulin to ensure equal loading.
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To determine whether expression o f these genes increases the rate of cellular
proliferation, in vitro proliferation of melanocytes expressing wt RSK, RSK-CAI,
RSK-CAII or NRAS (Q61R) was measured (Figure 4A). Wild-type RSK, RSK-CAII,
and NRAS (Q61R) expression all increased the rate of cellular proliferation
compared with the parental cells. Interestingly, cells expressing RSK-CAI decreased
the rate o f cellular proliferation compared with the parental cells.
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Figure 4. (A) In vitro proliferation of melanocytes expressing different genes. Uninfected
melanocytes (D6-MEL) or melanocytes expressing NRAS (Q61R), wt RSK, RSK CAI, or RSK CAII
were cultured in microtiter wells for the indicated time points and viable cells were quantitated using
the CellTiter 96 AQueous One Solution Cell Proliferation Assay by optical density readings at 490 nm
(data are represented as mean ± s.e.m.; n = 3).

Melanocytes expressing wt RSK or RSK-CAII are tumorigenic.
To determine whether expression o f these genes causes anchorageindependent growth, the cells were assayed for their ability to grow in soft agar.
Whereas the parental melanocytes and the melanocytes expressing RSK-CAI failed to
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grow in soft agar, melanocytes expressing NRAS (Q61R) formed numerous colonies
in soft agar, demonstrating that NRAS activation in melanocytes results in anchorageindependent growth, a characteristic of transformed cells. While wt RSK and RSKCAII also formed colonies in soft agar, they were smaller and significantly fewer in
number than melanocytes expressing NRAS (Table 1).

Table 1. Tumorigenicity of melanocytes expressing different components of
the MAPK pathway.
Cell lines

Soft-agar growth*

Tumors in nude micef

Maximal tumor
volume §

D6-MEL
0/8
NA
No
8/8
>
800
mm
NRAS
Yes
> 800 mm
RSK-wt
Yes
8/8
NA
RSK-CAI
No
0/8
< 10 mm3
RSK-CAII
Yes
6/8
> 800 nun
8/8
M14 {
Yes
*Cells (1.5 x 10 cells/well) were resuspended in 0.55% Noble agar in growth
medium and layered over presolidified 0.65% agar in a 6-well plate. After 4-week
culturing, colony formation was assessed.
f Athymic nude mice (n-8) were injected subcutaneously with 1 x 107 cells/mouse
of each cell line and monitored for tumor formation for 12 weeks.
§Mean maximal tumor volume as measured by length x width x depth.
£M14 human melanoma cells were used as a positive control.

Although anchorage-independent growth is indicative o f transformation, a
more stringent assay of tumorigenic potential is the ability to form tumors in vivo. To
determine whether expression of these genes in melanocytes results in tumor
formation in vivo, cells expressing NRAS (Q61R), wt RSK, RSK-CAI, or RSK-CAII
were injected subcutaneously into nude mice.

Melanocytes expressing NRAS

(Q61R), wt RSK, and RSK-CAII all formed tumors in nude mice but with
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significantly different efficiencies and latencies (Table 1, Figure 4B). As early as
three weeks post-injection, tumors were visible in mice injected with melanocytes
expressing constitutively active NRAS. In contrast, tumors were not visible in mice
injected with melanocytes expressing wt RSK or RSK-CAII until eight weeks post
injection. In addition, whereas 8/8 mice injected with melanocytes expressing NRAS
(Q61R) and wt RSK developed tumors, only 6/8 mice injected with melanocytes
expressing RSK-CAII developed tumors (Table 1). Furthermore, while 8/8 tumors in
the NRAS cohort reached 1,000 mm3, only 2/8 of the wt RSK tumors grew to that
size. Interestingly, whereas 6/8 of the mice injected with melanocytes expressing
RSK-CAII developed visible tumors eight weeks post-injection, none of these tumors
grew larger than 10 mm .
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RSK-CAII!
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40

50
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Figure 4. (B) In vivo tumor formation. Volumes are shown for tumors induced by subcutaneous
inoculation o f 1 x 107 cells/mouse for the cell lines indicated. Tumor size was evaluated by caliper
measurements, and tumor volume was calculated by length x width x depth.

68

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Tumor cells expressing wt RSK are aneuploid.
The slow kinetics o f tumor formation in mice injected with melanocytes
expressing wt RSK or RSK-CAII suggested that additional genetic alterations were
required for tumor growth in vivo. To define the genetic alteration(s) that mediated
the in vivo growth of melanocytes expressing wt RSK, subcutaneous tumors that grew
to volumes greater than 500 mm3 were isolated and established in culture. As an
initial quantification of nuclear DNA content, RSK tumor cell lines, melanocytes
expressing wt RSK, and untreated D6-MEL melanocytes were stained with
propidium iodide and analyzed by flow cytometry. Populations of RSK-expressing
D6-MEL cells contained homogenous amounts of DNA, with two histogram peaks
characteristic of diploid cells in Go/Gi and G2 /M phase (data not shown). The DNA
content of cells expressing wt RSK (prior to injection into mice) was
indistinguishable from untreated D6-MEL cells. In contrast, the DNA content o f cell
lines established from wt RSK expressing tumors indicated that between 55 and 65%
of the cells were aneuploid (Table 2). To further evaluate the DNA content in these
cells, reverse DAPI stained metaphase spreads from each cell line were analyzed
cytogenetically. While only 1/20 metaphases from the parental D6-MEL cell line was
4n, 12/20 metaphases from the RSK-wt cells were 4n. Likewise, 17/20 and 18/20 of
the metaphases from the RSK-wt tumor cells at passage 3 and 10, respectively, were
4n indicating significant aneuploidy in cells expressing wt RSK. The genomic
integrity o f the D6-MEL melanocyte cell line was also evaluated using spectral
karyotyping (SKY). Twenty metaphases were analyzed and 17/20 metaphases had an
additional chromosome 6 and 15, 18/20 metaphases had an extra derivative
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chromosome 4 translocated with chromosome X, and 1/20 was near-tetraploid, an
insignificant finding (Figure 5A, B, and C).
Table 2. DNA content of melanocytes and tumor cells.
Flow cytometry’
CytogeneticsT
Cell line
2n
4n
2n
4n
D6-MEL
100%
0%
95%
5%
60%
D6-RSK-wt
100%
0%
40%
85%
Tumor cells (p.3)
33.65%
65.18%
15%
43.87%
10%
90%
Tumor cells (p. 10)
56.13%
*Quantification of D SA content ?y propidium iodide staining o f nuclear DNA.
t Analysis of 20 rev<2 rse DAPI-s tained metaphase chromosome spreads.
Increased Met protein levels result from gene amplification.
Since amplification and/or overexpression of the receptor tyrosine kinases
(RTK) EGFR (7, 9) and M ET have been implicated in melanoma progression (8), we
evaluated the expression of EGFR and Met in the tumor cells expressing wt RSK.
While no difference in EGFR expression was observed (data not shown), a significant
increase in Met protein levels was detected by western blot (Figure 3B, right panel).
To determine if the mechanism of increased Met protein levels was the result of gene
amplification, we analyzed both interphase and metaphase cells by fluorescent in-situ
hybridization (FISH) using a probe specific for the Met locus. FISH analysis showed
3 copies of both the Met specific probe and the control probe in the D6-MEL parental
melanocytes and the melanocytes expressing wt RSK (Figure 5D). The 3 copies of
chromosome 6 correspond with the additional chromosome 6 detected by SKY in the
D6-MEL cells (Figure 5C). In contrast, a high level of intrachromosomal Met gene
amplification was detected in the RSK-wt expressing tumor cells; 46 copies were
detected in the 2n tumor cells and 92 copies were detected in the 4n cells. Reduced
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Met expression was observed with increased passage of the tumor cells in culture
(Figure 3B, right panel).
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Figure 5. Spectral karyotyping and M et FISH of melanocytes and tumor cells. A-C SKY
analysis of D6-MEL melanocytes. A. G-banding. B. Pseudocolored chromosomes. C. Chromosomal
pattern adjacent to the corresponding pseudocolored chromosome. D-G Met FISH analysis. D.
Interphase RSK-wt cell pre-implantation. E. Metaphase RSK-wt cell pre-implantation. F. Interphase
RSK-wt tumor cell. G. Metaphase RSK-wt tumor cell. Ten metaphases were analyzed per cell line. A
representative image is shown for each. Orange, probe detecting the Met locus on chromosome 6;
green, chromosome 6 control probe.
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Discussion
We observed that RSK is highly activated in several human melanoma cell
lines compared with normal melanocytes. Expression of wild-type (wt) RSK or a
constitutively active mutant of RSK (RSK-CAII) increases the proliferation of
Ink4a/Atf-mi\\ melanocytes in vitro and induces transformation in vivo. However,
tumor growth was significantly delayed compared with cells expressing activated
NRAS. The delayed tumor growth in the RSK expressing cells suggested that
additional genetic events were required. We compared tumors that grew to volumes
greater than 500 mm3 with the RSK expressing pre-injected cells and observed
overexpression of Met protein in the tumor cells. Cytogenetic analysis of RSKinduced tumors revealed high-level amplification of the RTK Met in all cases. This
amplification was intrachromosomal and was found only in tumors driven by
overexpression of wild-type RSK. Each explant had significant Met expression which
diminished over several passages.
It is interesting that only the melanocytes expressing wt RSK went on to form
tumors in vivo. While CA RSK mutants have activity in the absence o f MAPK
signaling, they have sub-maximal activity relative to wt RSK when MAPK is active
(22). Previously, we demonstrated that overexpression of wt RSK prevented
apoptosis equally as well as either CA-RSK in the presence of a MEK inhibitor in
human melanoma cell lines (11). The duration of RSK activity may be relevant as
RSK activity has been detected as long as two hours post stimulation (23). Therefore,
in an in vivo setting with transient MAPK activation, overexpression o f wt RSK is
sufficient to promote proliferation while partially active CA RSK mutants may be
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limited. Our data also show that the majority of active RSK-1 localizes to the nucleus
(Figure 2A) and suggest that a ratio o f the nuclear vs. cytoplasmic (N/C) staining
intensity can be used as a correlate with activation status of RSK-1 in tissues. This is
consistent with previous findings that upon activation, RSK translocates to the
nucleus, where it phosphorylates nuclear substrates (24-26). Although CAI and CAII
are equally able to phosphorylate a cytosolic substrate ( 1 1 ), the difference between
CAI and CAII may lie in the inability of myristoylated CAI to translocate to the
nucleus and phoshphoylate nuclear substrates, suggesting that the effects mediated by
RSK are nuclear. This idea is supported by the data in Figures 1 and 2, which
demonstrate that active RSK is in the nucleus.
The c-MET proto-oncogene encodes the receptor for Hepatocyte Growth
Factor/Scatter Factor (HGF/SF), which is known to mediate mitogenic, motogenic,
and invasive responses. Gene amplification of the RTK MET can be found in 10-20%
of primary human gastric cancers (27). In a Brcal/Trp53 mouse model, high level
Met gene amplification was observed in 73% of the mammary tumors (28) providing
further support for the relevance of secondary genetic events in tumorogenesis. While
infrequent in nevi and primary melanomas, 38% of metastatic lesions have significant
MET expression suggesting a role in tumor progression ( 8 ). Through its ability to
promote tumor progression and enhance invasiveness, MET is being developed as a
therapeutic target for drug intervention in many metastatic tumors including
melanoma. Recently, a MET-specific RTK inhibitor displayed promising antitumor
activity against melanoma cell lines expressing MET (29).
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CHAPTER IV
A NOVEL BH3 MIMETIC REVEALS A MAPK-DEPENDENT MECHANISM OF
MELANOMA CELL DEATH CONTROLLED BY P53 AND REACTIVE
OXYGEN SPECIES
This work appeared in Cancer Research 2006;

6 6

: (23). December 1, 2006.

Abstract
The RAS/BRAF/MEK/ERK mitogen activated protein kinase (MAPK)
pathway is emerging as a key modulator of melanoma initiation and progression.
However, a variety of clinical studies indicate that inhibiting the MAPK pathway is
insufficient per se to effectively kill melanoma cells. Here we report on a genetic and
pharmacological approach to identify survival factors responsible for the resistance of
melanoma cells to MEK/ERK antagonists. In addition, we describe a new tumor-cell
selective means to bypass this resistance in vitro and in vivo. By generating a panel of
isogenic cell lines with specific defects in the apoptotic machinery, we found that the
ability of melanoma cells to survive in the absence o f functional MEK relies on an
ERK-independent expression of the anti-apoptotic factor Mcl-1 (and to a lesser
extent,

B c 1 -x l

and Bcl-2). Using computer-based modeling, we developed a novel

Bcl-2 homology domain 3 (BH3) mimetic. This compound, named TW-37, is the first
rationally designed small molecule with high affinity for Mcl-1,

B c 1 -x l

and Bcl-2.

Mechanistic analyses of the mode of action o f TW-37 showed a synergistic tumor cell
killing in the presence o f MEK inhibitors. Importantly, TW-37 unveiled an
unexpected role of the MAPK pathway in the control of reactive oxygen species
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(ROS). This function was critical to prevent the activation of pro-apoptotic functions
of p53 in melanoma cells, but surprisingly, it was dispensable for normal
melanocytes. Our results suggest that this MAPK-dependent ROS/p53 feedback loop
is a point of vulnerability of melanoma cells that can be exploited for rational drug
design.

Introduction
The identification of tumor-associated genetic and epigenetic hallmarks is
providing a rational platform for molecularly targeted cancer therapies (1, 2). In
particular, the concept that tumor cells may remain dependent on the oncogenes that
promote cell transformation is being exploited for the design of more selective
anticancer agents (3). However, the identification of targets for drug development is
frequently challenged by the complex and heterogeneous background of neoplastic
cells. Malignant melanoma is a prime example of an aggressive tumor type
containing aneuploid cells which undergo a plethora of changes in gene expression
during malignant transformation (4). The extreme resistance of melanoma cells to
standard chemotherapeutic agents, either as single agents or in combination, has
hampered the identification of prognostic factors or predictors of treatment response
(5,6).
Further complicating drug design, the activation of the apoptotic machinery,
particularly the intrinsic or mitochondrial pathway, is defective in aggressive
melanoma cells (5, 7). For example, the activation of p53, a main modulators of this
pathway, can be compromised by upregulation o f negative regulators (e.g. HDM-2)
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( 8 ) or by defective positive effectors (e.g. 14-3-3 or p l4 ARF) (9, 10). Moreover,
multiple anti-apoptotic members of the Bcl-2 family (primarily

B c 1 -x l

and Mcl-1)

can act downstream o f p53 to prevent the release from the mitochondria of
Cytochrome c, Smac, AIF and other death inducers (5, 7). Additionally, inhibition of
caspases can result from the increased expression of several members of the IAP
(inhibitors of apoptosis proteins) family (11) and/or by downregulation o f APAF-1, a
cofactor of caspase-9 (12, 13). Overexpression of proteins such as survivin, that act at
the interface between cell cycle progression and death, can also contribute to the
aggressive phenotype of melanoma cells (7).
It is conceivable that key determinants of melanoma cell survival are acquired
in a progressive and independent manner at different stages of tumor development.
However, multiple alterations affecting the core o f the apoptotic machinery rely on
simultaneous transcriptional or post-translational events (affecting for example
members o f the Bcl-2 and IAP families) (5, 7). Therefore, it is possible that at least
some antiapoptotic events are collectively regulated. The identification of such
master regulator(s) could provide an ideal target for therapeutic intervention. In this
context, the RAS/BRAF/MEK/ERK (MAPK) pathway is raising high expectations
for the rational design of more effective anti-melanoma therapies (14-16). This
pathway is invariably activated in early, intermediate and late stage melanomas (see
Ref (17) for review), and dysregulated MAPK signaling contributes to the resistance
of melanoma cells to a variety of chemotherapeutic agents (15, 18,19). However, the
precise contribution of downstream targets of ERK to melanoma cell survival is not
well understood.
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In a variety of tumor cell types, ERK can block apoptosis by favoring the
transcription and activation of anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-xL and Mcl1), or by inhibiting pro-apoptotic factors such as BimeL or Bad (20-22). BRAF and
ERK have also been reported to interfere with events acting downstream of the
mitochondria, ultimately preventing the activation of caspase-9 and the execution of
cell death (19, 23). However, while BRAF, MEK or ERK inhibitors can efficiently
block melanoma cell proliferation (14, 15, 24), the killing activity of these
compounds may be limited to selective groups of melanoma cells (25-27). Thus, the
inhibition o f MEK may be ineffective as a death inducer in melanoma cells lacking
BRAF mutations (which constitute the majority of acral or mucosal melanomas and
to more than 30% of cutaneous melanomas) (4). Moreover, melanoma clinical trials
with famesyltransferase inhibitors (to block RAS signaling), sorafenib (which inhibits
CRAF and BRAF) or the MEK inhibitor PD-0325901 have demonstrated only
modest clinical impact as single agents (see R ef (28) for review). Therefore,
identifying new compounds that can bypass the resistance to MAPK inhibition can
have a major impact in melanoma therapy.
In order to investigate the interplay between the MAPK pathway and the
apoptotic machinery of melanoma cells, here we used lentiviral-driven short
interfering RNAs (shRNA) to generate isogenic lines with specific defects in the
apoptotic machinery. This strategy allowed for the identification of Mcl-1,

B c 1 -x l

and

Bcl-2 as main mediators of the resistance to MEK inhibition. Since no synthetic
inhibitor of Mcl-1 has been described, we used a computational approach to generate
TW-37, the first rationally designed BH3 mimetic able to block Mcl-1,

B c 1 -x l
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and

Bcl-2. TW-37 and MEK inhibition synergistically killed aggressive melanoma cell
lines, with minimal secondary toxicity for normal skin cells (melanocytes,
keratinocytes and fibroblasts). We present a comprehensive characterization of the
molecular basis underlying the synergistic interaction between TW-37 and inactive
MEK/ERK. Our studies revealed an unexpected tumor-cell selective role of the
MAPK pathway upstream of the mitochondria, controlling ROS production and the
activation of proapoptotic functions of p53. Our findings demonstrate the power of
RNA interference and rational pharmacologic approaches to overcome melanoma
chemoresistance.
Materials and Methods
Cell culture.
The non-metastatic WM-1366 cell line and the metastatic melanoma lines
Malme-3M, UACC-62, G361, UACC-257 and the SK-Mel series (SK-Mel-19, -28, 29, -94, -103, -147, -173) were cultured in Dulbecco’s modified Eagles’s medium
(DMEM) (Life Technologies, Rockville, MD) supplemented with 10% fetal bovine
serum (Nova-Tech, Inc., Grand Island, NY). Human melanocytes were isolated from
human neonatal foreskins as described (29) and maintained in Medium 254
supplemented with 10 nM TPA and melanocyte growth factors (Cascade Biologies,
Portland, OR). Melanocytes were also incubated in DMEM-10% fetal bovine serum
for direct comparison to melanoma cells. Keratinocytes and fibroblasts were also
freshly isolated from foreskins. Keratinocytes were maintained in media 154
supplemented with keratinocyte growth factors (Cascade Biologies). Fibroblasts were
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grown in DMEM supplemented with 10% fetal bovine serum. Specific details
regarding the sequencing of BRAF and NRAS is indicated in the Supplementary
Information section.
Reagents.
The

MEK

inhibitor

4-diamino-2,3-dicyano-l,4-bis(2-

aminophenylthio)butadiene (U0126) was purchased from Calbiochem (La Jolla, CA).
The MEK inhibitor Cl-1040 was from Pfizer (Ann Arbor, MI), and doxorubicin
hydrochloride (adriamycin) was from Fisher Scientific (Fair Lawn, NJ). The cell
permeable pan-caspase inhibitor zVAD-FMK (Z-Val-Asp(OMe)-FMK) was from MP
Biomedicals (Aurora, OH). The antioxidant 4,5-dihyroxyl-l,3-benzenedisulfonic acid
disodium salt monohydrate (Tiron) and (+)-6-hydroxy-2,5,7,8-tetramethylchromane2-carboxylic acid (Trolox) from Sigma-Aldrich (St. Louis, MO). The ROS indicator
5-(and -6)-chloromethyl-2’, 7’-dichlorohydrofluorescein diacetate, acetyl ester (CMH2 DCFDA) was purchased from Molecular Probes (Eugene, OR).
Design and binding assays for TW-37.
The detailed design and synthesis of TW-37 have been described elsewhere
(G. W., Z. N-C., C. Yang, R. Wang, G. Tang, J. Gao, S. Shangary, S. Qiu, W. Gao, J.
Meagher, J. Stuckey, K. Krajewski, S. Jiang, P. Roller, H.O. Abaan, Y. Tomita. S.W.,
in press). Binding affinities o f TW-37 and TW-37i to purified Bcl-2,

B c 1 -x l

and Mcl-

1 were determined by competitive fluorescence-polarization-based binding assays. In
short, a Bid BH3-containing peptide (residues 79-99) was labeled at the N-terminus
with

6

-carboxyfluorescein succinimidyl ester (FAM). 1-2.5 nM FAM-Bid peptide

were preincubated with 40 nM Bcl-2, 30 nM Bcl-xL or 5 nM Mcl-1 in assay buffer
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(100 mM potassium phosphate pH 7.5; 100 pg/ml bovine gamma globulin; 0.02%
sodium azide). Polarization values in milipolarization units (mP) were measured in
Dynex 96-well, black, round-bottom plates (Fisher Scientific) in the absence or in the
presence of increasing concentrations o f TW-37 (excitation wavelength=485 nm and
emission wavelength=530 nm) using a Ultra plate reader (Tecan U.S. Inc., Research
Triangle Park, NC). Purified protein or fluorescent probes were also included as
reference controls. K{ values were calculated with GraphPad Prizm 4 software
(GraphPad Software, San Diego, CA) using previously described equations
(http://sw 16.im.med.umich.edu/software/calc_ki/) (30).
Drug teatments and cell viability.
Cell viability assays in response to drug treatments were performed after
seeding human melanocytes or melanoma cells at least 18 h prior to drug treatment.
Drug assays routinely used the small molecule inhibitor TW-37 at a final
concentration of 5 pM and the MEK inhibitor U0126 at a final concentration of 10
pM. Drug combination assays included a pre-treatment step with TW-37 for 12 h
prior to the addition of U0126. For simplicity, vehicle control treated cells are
indicated as “non treated” (NT). Time dependent studies were considered to begin
upon the addition o f U0126 (t=0 h). Controls for DNA damage included adriamycin
at a final concentration of 0.5 pg/ml. Cell death resulting from drug treatments with
single agents, combination agents or vehicle alone was estimated by MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) or standard Trypan Blue
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exclusion assays as previously described (12, 31, 32). Experiments were performed in
triplicate and data are presented as the average ± SEM.
Cell cycle analyses.
Cells were harvested following appropriate drug treatments and fixed with 1
mL of ice-cold 70% ethanol. Cells were washed twice with PBS, followed by
incubation in a labeling solution o f 50 pg/mL propidium iodide (PI) (Sigma
Chemical, St. Louis, MO), in PBS containing 0.2% Triton and 10 pg/mL RNase A.
PI fluorescence was analyzed using a FACS Calibur flow cytometer and cell cycle
distribution was determined using Cell Quest software (Becton Dickinson, San Jose,
CA).
Protein immunoblots.
Adherent and non-adherent cells were collected by either scraping or
trypsinization and pelleted by centrifugation at 800g for 3 min. Total cell lysates were
obtained by Laemmli extraction (31, 32). Protein samples were separated on 12% or
4-20% gradient SDS polyacrylamide gels and transferred to Immobilon-P membranes
(Millipore, Bedford, MA). Alternatively, mitochondrial and cytosolic cell fractions
were prepared by digitonin extraction as previously described (32). Sixty pg of the
cytosolic fractions were used for immunoblot analysis of the release o f proapoptotic
proteins from the mitochondria, a-tubulin or p-actin were included as loading
controls.
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Stable short hairpin interfering RNA constructs (shRNA).
Published references were used as a guide to generate short 19 bp hairpins for
RNA interference: Bcl-2, nt 500-518, GenBank M13995 (33);

B c 1 -x l,

nt 714-732,

GenBank BC019307 (34); p53, nt 611-629, GenBank NM000546 (35); BAK, nt 535553, GenBank NM001188 (36). Oligos against Mcl-1 (nt 2343-2361, GenBank
NM021960), BAX (nt 239-257, GenBank NM138761), were generated using the
OligoRetriever database (http://katahdin.cshl.org:933l/RNAi_web/scripts/main2.pl).
BLAST search was performed to ensure at least 4-nt differences with annotated
human genes. The corresponding oligonucleotides were annealed and cloned under
the control of the HI promoter into a self-inactivating lentiviral vector (37). The
vector was also designed to carry the GFP reporter gene under control of the human
ubiquitin-C promoter to monitor infection efficiency. A scrambled shRNA construct
was also designed to be used as a control. Lentiviral infections were performed
essentially as described elsewhere (37) and the potency and specificity of each
construct was determined by protein immunoblotting (see text). Primer sequences,
cloning strategies, as well as transfection and infection strategies are available from
the authors upon request.
Immunofluorescent visualization o f activation-dependent conformational changes of
BAX.
Cells of interest were seeded onto glass culture slides and treated with TW-37
(5 pM) in the presence or absence of U0126 (10 pM). Antioxidants were added as
indicated. Cells were fixed with 4% formaldehyde at different time points after
treatment, permeabilized with 0.2% Triton-X in PBS for 5 min and washed three
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times with PBS. Following a 30 min blocking step in 1% BSA, the rabbit polyclonal
Bax-NT antibody from Upstate Biotechnology (Lake Placid, NY) was used to
visualize conformational changes in BAX following previously described protocols
(38, 39). Melanoma cells rounded up and floated immediately after Cyt c release (not
shown). To avoid for indirect effects on BAX conformation as byproducts of cell
death, only adherent cells (corresponding to early apoptotic cells) were analyzed. The
percent of cells with positive staining was estimated using vehicle-treated cells as a
reference.
Detection of ROS production by fluorescent microscopy.
Melanoma cell lines and melanocytes were seeded onto glass culture slides
(BD Biosciences, Bedford, MA) and treated with the indicated drugs. At various time
points, media was aspirated and cells were loaded with 1 pM CM-H2 DCFDA in PBS
for 10 min at 37°C in the dark, followed by a PBS wash step essentially as previously
reported (31). 0.03% FI2 O2 was used as a reference control for an active ROS inducer.
DCF-dependent fluorescence was scored with ImageJ software and expressed with
respect to untreated control cells.
Indirect measurement of oxidized proteins.
Following drug treatments both adherent and non-adherent cells were
collected and subjected to Laemmli extraction. Oxidized proteins were visualized by
derivatization of carbonyl groups with dinitrophenylhydrazine (DNPH) using the
OxyBlot Oxidized Protein Detection Kit (Chemicon International, Temecula, CA)
according to the manufacturer’s instructions. Following SDS-PAGE separation and
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standard Western blotting, the resulting DNP-hydrazone side chains were detected
with a specific antibody to the DNP moiety o f the protein.
Melanoma growth in vivo (Mouse xenoeraphs).
Athymic NCr-nu/nu mice (NCI) were kept in pathogen-free conditions and
used at 8-12 weeks of age. Animal care was provided in accordance with the
procedures outlined in the Guide for the Care and Use of Laboratory Animals o f the
University o f Michigan. To analyze localized melanoma growth in vivo, 0.5xl0 6
GFP-expressing SK-Mel-147 melanoma cells were injected subcutaneously (s.c) in
both rear flanks (n=12 tumors per experimental condition). Treatment was initiated
on the third day following cell implantation (when tumors were palpable) and
continued until day 20 with a one day resting period every 5 days. TW-37 was
resuspended in 1:1 Tween 80:ethanol (diluted 10-fold in 0.9% saline prior to use) and
administered daily at 40 mg/kg alternating intravenous or intraperitoneal injections.
C l-1040 was resuspended in 8:1:1 H2 0 :ethanol:Cremophor and administered by oral
gavage twice per day at 75 mg/kg, as described (32). Control and single agent animal
groups received vehicle treatments. Imaging of tumor cells in vivo was performed
with an Illumatool TLS LT-9500 fluorescence light system (Lightools Research,
Encinitas, CA) and the emitted fluorescence from tumor cells was captured with a
Hamamatsu Orca 100 CCD camera. Volume of the s.c xenografts was estimated as
V=LxW 2 /2, where L and W stand for tumor length and width, respectively.
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Statistics.
Statistical analyses of drug response in mouse xenograft models were
performed using the SAS statistical software (SAS Institute, Inc. Cary, NC). The
Tukey’s HSD test was used for pairwise comparisons among groups, and the Dunnett
test for individual comparisons to untreated controls. The type I error rate was set at
0.05.
Mutational status of BRAS and NR AS.
BRAF and NRAS mutations were identified by PCR amplification of genomic
DNA followed by sequencing. Briefly, PCR products generated by standard methods
were cleaned up by treatment with shrimp alkaline phosphatase (Roche Applied
Sciences) and exonuclease I (Epicentre Technologies, Madison, WI), and sequenced
with the BigDye Terminator sequencing protocol (Applied Biosystems, Foster City,
CA). For BRAF, primers TCATAATGCTTGCTCTGATAGGA (forward) and
GGCCAAAAATTTAATCAGTGGA (reverse) were used for both PCR and
sequencing.

For

NRAS,

PCR

was

AAGGGGGATTT CC ATT GCTTAG

performed
and

with

forward

reverse

primer
primer

TGGGTAAAGATGATCCGACAAGTG, followed by sequencing using nested
primers

CCAAATGGAAGGTCACACTAGGG

and

AGTGAGAGACAGGATCAGGTCAGC. Sequences were assembled and examined
using the Seqman component of DNAStar sequence analysis package (DNAStar,
Madison, WI).
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Primary antibodies.
Antibodies for Caspase-9 and Survivin were from Novus Biologicals
(Littleton, CO); Caspase-3, Caspase-7, PUMA (Ab2), phospho-histone H2A.X (Ser
139), phospho-p53-Ser15, phospho-extracellular signal-regulated protein kinase
(ERK) 1/2 (Thr2002/Tyr204) and total ERK1/2

from Cell Signaling Technology

(Beverly, MA); Bim/BOD from Imgenex™ (San Diego, CA); BAX and BAK from
Upstate Biotechnology (Lake Placid, NY); Cyt c (7H8.2C12) and

B c 1 -x l

(clone pAb)

from BD Biosciences (Franklin Lakes, NJ); AIF (E-l) from Santa Cruz
Biotechnology (Santa Cruz, CA); Bcl-2 from Dako Diagnostics (Glostrup, Denmark);
Smac/DIABLO (222-237), Noxa and Caspase- 8 (Ab-3) from Calbiochem (San
Diego, CA); p53 (CM-1) from Novocastra Laboratories (Newcastle upon Tyne, UK);
PUMA (A bl) from eBioscience (San Diego, CA); and tubulin and P-actin (AC-74)
from Sigma Chemical (St Louis, MO). The corresponding antibody signal was
revealed with the ECL system from Amersham Biosciences (Amersham, Arlington
Heights, IL).

Results
Identification of melanoma cell lines resistant to inhibition of the MAPK pathway.
It has been recently reported that NRAS and BRAF-expressing melanoma
cells have a different sensitivity to inhibitors of the MAPK pathway (25). Thus,
metastatic melanoma cells with NRAS mutations have an increased resistance to RAF
and MEK inhibitors (25). To identify poorly responsive cells and address the
molecular basis underlying the resistance to MAPK inhibition, a panel o f 11
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melanoma cell lines was sequenced for the most frequent mutational hotspots in the
NRAS and BRAF genes (i.e. exons 3 and 15, respectively; see Figure 1A, B). The
individual cells lines were subsequently compared in their response to the MEK
inhibitor U0126 (40), which blocks ERK activation downstream of NRAS or BRAF
(Figure 1C). U0126 was able to inhibit cell proliferation (Figure 1A) by a G l/S
mediated cell cycle arrest in NRAS and BRAF mutated cells (Figure ID). However,
the killing activity of U0126 was even less efficient than expected. Thus, at
concentrations required to maintain the viability of normal melanocytes, the NRASmutated cells and 3 out 5 BRAFv600E-expressing melanoma lines responded poorly to
U0126 (Figure IB). In fact, the overall killing activity by this MEK inhibitor was not
significantly different from standard chemotherapeutic drugs such as Adriamycin
(Figure IB). Two of the most resistant lines (SK-Mel-103 and -147) were chosen as
representative examples to identify survival mechanisms acting in the absence of
ERK activation, and to test new compounds able to overcome melanoma
chemoresistance.
Anti-apoptotic factors retained after ERK inhibition.
Despite the ability of U0126 to block ERK phosphorylation, it was possible
that downstream apoptotic targets (e.g. BimEL,

B c 1 -x l,

Bcl-2 or Mcl-1) were not

affected by treatment, and consistently, did not favor cell death. To address this
possibility, protein extracts were prepared from melanoma cells at different points
after incubation with U0126. As shown in Figure IE, although BimEL was induced by
U0126, Bcl-2 and

B c 1 -x l

were still detectable at late times after treatment and Mcl-1

levels did not significantly change (Figure IE). With respect to other apoptotic
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Figure 1. Cytostatic effect of the MEK inhibitor U 0126 on metastatic melanoma lines. (A)
Dose-response curves o f the indicated melanoma cell lines estimated by MTT assay 48h after
treatment. Cell code is indicated in materials and methods. Cells were grouped according to wild
type (blue) or mutant V600E (red) BRAF status. (B) Cytotoxicity o f U0126 (10 pM) or adriamycin
(0.5 pg/mL) on normal melanocytes (Mel) and a panel o f metastatic melanoma lines o f either wild
type (wt) or mutant (mut) BRAF and NRAS. U-62 and M-3M stand for lines UACC-62 and Malme3M, respectively. The rest o f the cell lines correspond to SK-Mel-series. Cell death was assayed by
Trypan Blue exclusion 48 h after treatment. (B) Visualization by protein immunobloting o f the
inhibitory effect o f U0126 (10 pM, 24 h) on phosphorylated ERK1/2 (p-ERKl/2). Total ERK1/2 and
□ -actin are shown as controls for protein loading. (D) Cell cycle distribution determined by flow
cytometry o f control (no treatment, NT) and U0126 (10 pM) treated melanoma cells. Shown are the
percentage o f viable cells at the Go/Gi, S and G2/M phases. (E) Impact o f U0126 (10 pM) on
apoptotic modulators as a function o f time. Shown are representative SDS-PAGE gels.
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Stable RNA interference for target validation.
To determine the relative contribution of Mcl-1, Bcl-2 ans

B c 1 -x l

to U0126-

mediated resistance, a lentiviral-mediated approach was used to stably express
specific short interfering RNAs (shRNA) in melanoma cells. To allow for imaging of
infected cells, the lentivirus used (KH1-LV) co-expressed eGFP under an
independent UbC promoter (Figure 2A, B). Constructs able to promote a reduction of
more than 80% of the intended protein expression without affecting the level of other
Bcl-2 family members are shown in Figure 2C.
Acute inactivation of Bcl-2,

B c 1 -x l

or Mcl-1 by shRNA, significantly

enhanced the response of melanoma cells to U0126 (Figure 3A). Interestingly, the
most effective cytotoxic effect was found after inactivating Mcl-1 (Figure 3A),
consistent with this protein remaining highly expressed in melanoma cells after
treatment with U0126 (Figure IE).
Altogether, these results indicate that despite the multiple genetic defects that
melanoma cells harbor, the resistance to MEK/ERK inhibition is primarily dependent
on Mcl-1, and to a lesser extent B c 1 - x l and Bcl-2.
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Figure 2. Tumor-ceU selectivity of TW-37/U0126. (A) Long-term assays o f the impact o f acute
TW-37/U0126 on normal melanocytes and SK-Mel 103. Cells were left untreated or treated with 5
pM TW-57 and 10 pM U0126 for 40 h. Drug was removed (red arrow) and cell number was
estimated at the indicated time points and plotted with respect to the initial amount o f seeded cells.
(B) Comparative analysis o f the sensitivity o f normal skin melanocytes, keratinocytes and
fibroblasts with respect to a representative metastatic melanoma cell line (SK-Mel-103). The three
normal cell populations maintained their viability under conditions that promote the killing o f
tumor cells. Note that cell killing was not substantially affected by the growth media MGM, KGM
and DMEM stand for melanocyte growth medium, keratinocyte growth medium (Epilife) and
Dulbecco’s Modified Eagle medium, respectively. See Materials and Methods for additional
information about culture conditions o f normal skin cells and malignant melanoma cells.
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Pharmacological enhancement of the response of melanoma cells to UP 126: Design
and validation of new BH3 mimetics.
Small molecule inhibitors that interfere with anti-apoptotic members of the
Bcl-2 family are emerging as a powerful anticancer strategy (43). Nevertheless,
published synthetic BH3 mimetics either do not recognize or bind poorly to Mcl-1
(44-46). Therefore, we utilized a structure-based methodology to generate novel non
peptide small molecules able to bind Mcl-1 as well as Bcl-2 and

B c 1 -x l

(to improve

efficacy). Our approach was based on the reported ability of the BH3 domain of the
pro-apoptotic Bim protein to bind in a promiscuous manner to Mcl-1,

B c 1 -x l

and Bcl-

2 (43, 47). Using the structure of Bim for computational docking and molecular
dynamics a series o f putative BH3 mimetics were designed, of which the compound
TW-37 (Figure 3B) was chosen for displaying a high cell permeability (not shown).
Fluorescence polarization-based competitive binding assays were performed
to address the ability of TW-37 to displace short peptides containing the BH3 domain
o f Bim or Bid from Bcl-2,

B c 1 -x l

or Mcl-1. Representative examples o f binding

curves are shown in Figure 3B. TW-37 was found to bind Mcl-1,

B c 1 -X l

and Bcl-2

with Ki values of 260 nM, 1100 nM, and 120 nM, respectively (Figure 3C and results
not shown). Based upon computer modeling of X-ray structures of BH3-binding
domains, the three hydroxyl groups in TW-37 were expected to play a crucial role in
its interaction with BH3 domains. Consequently, to control for unspecific effects of
the TW-37 backbone, a derivative (TW-37i), was generated in which the three
hydroxyl groups were methylated (Figure 3B). As shown in Figure 3C, the Ki of TW-
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37i for Bcl-2 was two orders of magnitude higher than TW-37 (Figure 3B).
Therefore, TW-37i was used as an inactive control.
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Figure 3. TW-37 as a novel class o f BH3 mimetics. Tumor-cell selective enhancement o f the
cytotoxic effect o f U0126. (A) Molecular structure o f the small molecule inhibitor TW-37 and the
inactive TW-37i derivative. (B) Binding kinetics o f TW-37 to the anti-apoptotic Bcl-2, B c1-X l and
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obtained from indicated drug administered as a single agent and tested in MTT assays (see
Materials and Methods). Note that the data points corresponding to combination treatments fall
below the line o f additivity (broken line), indicating a supra-additive (synergistic) interaction.
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Selective and synergistic killing of melanoma cells by U0126 and TW-37.
Aggressive melanoma lines such as SK-Mel-103 and SK-Mel-147 could be
killed with TW-37 at concentrations of 10 pM (not shown). Interestingly, lower drug
concentrations, although inducing minimal toxicity, were found to be highly
synergistic with U0126 (see isobolograms at EC 50 and ECgo in Figure 3D, and
representative microphotographs of treated cells in Figure 3E). Confirming the BH3binding features of TW-37, the inactive TW-37i was unable to synergize with U0126
(Figure 3E).
U0126

0

E

10

TW-37+U

TW-37i+U

15

TW-37 (piM)

Figure 3 continued. TW-37 as a novel class of BH3 mimetics. (D) Cytotoxicity o f TW-37 or the
inactive TW-37i variant (5 pM each) in the absence or presence o f U0126 (10 pM). Shown are
microphotographs o f the indicated melanoma cell lines or normal control melanocytes 40 h after
treatment. Note the preferential toxicity o f TW-37/U0126 towards the tumor cells (see Figure 2 for
long-term effects o f the different treatments). (E) Genetic inactivation o f Bcl-2, Bcl-xL or Mcl-1 by
RNA interference synergizes with U0126. Shown are the death responses o f the indicated
melanoma cell populations in the absence (white bars) or presence (grey bars) o f U0126 (10 pM,
48 h). Cell death was assayed in triplicate by Trypan Blue exclusion. Shown is the extent o f cell
death relative to shRNA scramble control-infected cells.
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Notably, the U0126/TW-37 combination was well tolerated by melanocytes in
after short-term treatments (Figure 3E) and long-term clonogenic assays (Figure 4A).
Normal skin fibroblasts and keratinocytes were also resistant to U0126/TW-37,
further illustrating the selectivity of this drug combination towards tumor cells
(Figure 4B).
Importantly, in melanoma cells, the combination of TW-37/U0126 induced
hallmarks of apoptosis, including a synergistic processing of regulatory and effector
caspases and (Figure 5A) and classical chromatin condensation and formation of
apoptotic bodies (Figure 6 ). It should be noted, however, that an important fraction of
cells could still die in the presence of the pan-caspase inhibitor zVAD-fmk (Figure
5B). This feature of the TW-37/U0126 combination may be advantageous to kill
melanoma cells even under conditions of defective caspase activation -which has
been proposed as a main contributor to the resistance to standard chemotherapeutic
agents (5, 7).
Mechanistic analyses of the TW-37/U0126 combination. Release of pro-apoptotic
factors from the mitochondria.
The enhanced activity of TW-37 in the presence of U0126 prompted us to
address the interplay between BH3-containing proteins and the MAPK pathway. An
attractive feature of BH3 mimetics as anti-cancer agents is their potential ability to
promote cell death by favoring the release of Cytochrome c (Cyt c) and other
mitochondrial death inducers by directly activating BAX and BAK (47).
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Figure 6. Inhibitory effect of antioxidants on BAX activation. Conformational changes o f BAX
determined by immunostaining with the BAX-NT antibody in the presence or absence o f TW-37, U0126
or the TW-37+U0126 combination. The antioxidants Troiox (20pM, red line) or Tiron (1 mM, blue line)
significantly reduced the amount o f cells with active BAX expression. Data corresponds to percentage o f
adherent cells (early apoptotic) with positive staining. Note that these results underestimate the difference
between cells treated in the absence or the presence o f antioxidants. Floating cells (which constitute the
largest fraction o f cells at later time points after incubation with TW-37 and U0126; see Figure 8B)
collapse and are not scored to avoid for secondary events that could affect indirectly BAX conformation
and localization after cell death.
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the mitochondria, shifting the detection of cytosolic Cyt c by immunoblotting from 40
h to as early as 6 h post-treatment (Figure 7A, see also Figure 7B and Figure 6 for
representative analysis of the visualization of Cyt c release by immunofluorescence).
Subsequent activation of BAX/BAK was important for TW-26/U0126 mediated cell
death, since downmodulation of these apoptotic factors favored melanoma cell
survival. Thus, shRNA-expressing lentiviruses were generated to block BAX or BAK
expression by RNA interference (Figure 7C,D). shRNA of BAX reduced by 50% the
killing activity of TW-37/U0126 in line SK-Mel-103, (Figure 7E, left panel). SKMel-147 required BAX and BAK for the induction of cell death, since shRNA against
each of these proteins reduced TW-37/U0126-driven cell killing (Figure 7E, right
panel).
A

B
TW+U

T resident

UC126

Time ip}

C y tc

Sm ac
AIF
Tubulin
% C-sll D sa

Figure 7. Classical BH3-mimetic features of TW-37. BAX/BAK-dependent activation o f the
mitochondrial apoptotic pathway. (A) Time course illustrating the release o f mitochondrial
apoptotic effectors Cyt c, Smac and AIF in response to the indicated treatments. Shown are
representative SDS-PAGE gels o f cytosolic extracts isolated by digitonin fractionation. (B)
Visualization o f Cyt c release from the mitochondria (white arrows) by immunofluorescence.
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Blue exclusion assay 40 h post drug treatment. Data correspond to the mean ± SEM o f three
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Impact of MEK/ERK inhibition upstream of BAX.
BRAF and ERK have been reported to act downstream of Cyt c or Smac to
control caspase activation (19, 23). However, the synergistic effect of U0126 on Cyt c
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release suggest an additional role of the MAPK upstream of the mitochondria,
controlling BAX/BAK activation. To this end, we used antibodies that can
specifically recognize conformational changes associated to pro-apoptotic activation
of BAX by immunofluorescence staining (38, 39). We specifically focused on BAX
as it contributed to the death of SK-Mel-103 and -147. Interestingly, at the dose and
treatment regimen in this study, no significant activation of BAX by TW37 was
detected unless in the presence U0126 (Figure 8). Thus, the TW-37/U0126 increased
by 7 to 10-fold the percentage expressing conformationally active BAX in SK-Mel147 and SK-Mel-103, respectively. These results suggest a new role of MEK/ERK in
the control of BAX and the mitochondrial pathway in melanoma cells.
Reactive oxygen species ('ROS') modulating the cytotoxic effect of TW-37/U0126.
Dysregulation of cellular redox mechanisms can be potent activators of
caspase-dependent and independent forms of cell death (48). Therefore, we tested the
possibility that MEK inhibition was cooperating with TW-37 in allowing for ROS
accumulation. Towards this end, drug treatments were performed in the presence
potent antioxidants. Two structurally unrelated antioxidant were used: Tiron, a spin
trap, and Troiox, a water-soluble Vitamin E analog (31). When added simultaneously
with TW-37 both of these antioxidants blocked TW-37/U0126 drug synergy,
preventing BAX activation (Figure 8A) and significantly reducing the kinetics and
extent of cell death by TW-37/U0126 (Figure 8B and results not shown). Note that
the inhibition of cell death by Tiron or Troiox was stronger than the blockage of
caspases by zVAD (Figure 4) or BAX and BAK, suggesting a key role of ROS in
TW-37/U0126 mediated cell death.
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Figure 8. ROS production modulates the cytotoxic effect o f TW-37/U0126. (A)
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Nuclear staining is shown by DAPI. (B) Effect o f antioxidants on cell death induced by TW-37 +/U0126 in the presence or absence o f Tiron (1 mM) or Troiox (200 pM). Cell death (%) was
determined by Trypan Blue exclusion 40 h after treatment.

The protective effect of Tiron or Troiox was compromised if they were added
12 h after treatment (not shown), suggesting an early contribution o f ROS to
melanoma cell death by TW-37/U0126. Production of ROS by TW-37 and further
enhancement by U0126 was visualized in cultured cells with the oxidation-sensitive
fluorescent probe CMH2 DCF-DA (see below in Figure 10B). These data are
intriguing because they implicate a MAPK-dependent control o f ROS production that
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cooperates with anti-apoptotic Bcl-2 family proteins in the maintenance o f melanoma
cell viability.
ROS-dependent activation of p53 by TW-37/U0126.
ROS are notorious for the pleiotropic effects that can elicit in mammalian
cells. To identify direct mediators of ROS-driven cell death among a plethora of
byproducts of changes in cellular redox, we focused on pro-apoptotic factors whose
expression is induced at early time points after TW37/U0126 treatment, but can be
blocked by antioxidants. A protein that followed this expression pattern was p53. As
shown in Figure 8C and 8D, TW-37 was able to induce sustained expression o f p53
in SK-Mel-103 and -147. Interestingly, the addition of U-0126 to TW-37 enhanced
12 to 15-fold by the addition of U0126 (Figure 8C, D). Notably, this induction of p53
was reduced by 80% in the presence of Troiox (Figure 8C, D). Therefore, our results
are consistent with the BH3 mimetic TW-37 and the MEK inhibitor U0126 activating
p53 via ROS production.
To confirm the requirement of p53 for TW-37/U0126 mediated melanoma cell
death, p53 protein expression was downmodulated by highly effective lentiviral
vectors (Figure 9A). Of note, p53 knockdown provided a protection from melanoma
cell death by about 75% (Figure 9B), and significantly reduced the activation and
translocation of BAX by TW-37/U0126 (Figure 9C). This is in contrast to standard
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Figure 8 continued. ROS production modulates the cytotoxic effect o f TW-37/U0126. (C)
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inhibitory effect o f Troiox on the ability o f TW and TW+U to induce p53. No changes in the total
expression o f BAX were observed. /?-actin was included as a loading control.

chemotherapeutic agents such as Adriamycin, etoposide or cisplatin which can induce
p53 but cannot effectively engage the apoptotic machinery in aggressive melanoma
cells (5, 7, 32).
p53 and ROS define the tumor cell-selective toxicity of TW-37/U0126.
As melanocytes do not die in response to TW-37/U0126 (Figure 3D), a
corollary of our results is that the activation of the ROS/p53 apoptotic loop is
restricted to tumor cells. To evaluate this possibility, normal melanocytes where
compared in their response to melanoma cells. While a significant accumulation and
activation (by phosphorylation) of p53 could be easily detectable in melanoma cells,
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109

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

normal melanocytes remained unaffected by TW-37, U0126 or the combination of
both agents (Figure 10A, B). Furthermore, the redox indicator CM-H2 DCF-DA
revealed a striking difference in the production o f ROS by melanoma cells and
normal melanocytes. Thus melanocytes remained negative for the production of
oxidized DCF-dependent fluorescence even at late times post treatment with TW37/U0126 (Figure IOC and results not shown). Yet, melanocytes could respond to
strong ROS inducers such as H 2 O2 (not shown). With respect to mock-treated
controls, melanoma cells incubated with TW-37 showed a 3-fold increase in the
DCF-dependent signal, which was doubled in combination with U0126 (Figure IOC,
right graph).
To further validate the differential ability of melanocytes and melanoma cells
to produce and respond to ROS induction, global expression o f oxidized proteins was
monitored by protein immunobloting. Specifically, the presence of carbonyl groups
(generated by oxygen free radicals and other reactive species) was visualized after
derivatization reactions with 2,4 dinitrophenylhydrazine (DNPH) and staining with
anti-DNP antibodies. Interestingly, the basal levels of DNP-dependent staining were
found to be already higher in untreated melanoma cells than in melanocytes (Figure
10D). Treatment of melanoma cells with TW-37, but not the inactive TW-37i led to a
noticeable increase in oxidized proteins that was further exacerbated by U0126
(Figure 10D). Importantly, no such changes were observed in normal melanocytes.
Together, our results identify a new BH3 mimetic (TW-37) as a novel strategy to
exploit the differential redox metabolism o f melanocytes and melanoma cells and
subsequent activation of p53-mediated death programs.
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General impact of MEK inhibitors on TW-37 mediated cell death. Anti-cancer
activity in vivo.
U-0126 has been broadly used as a MEK inhibitor. However, to discard
putative unspecific effects of this compound, additional viability studies were
performed with Cl-1040, a structurally different MEK inhibitor (49). Notably, and as
the case of U-1026, C l-1040 was able to promote a tumor-cell selective killing of
melanoma cells in the presence of TW-37 (Figure 11A, B). Thus, CI-1040 enhanced
by 5 fold the death of TW-treated melanoma cells without affecting the viability of
normal melanocytes (Figure 11A). Moreover, confirming the results with U0126, the
synergistic effect of CI-1040 and TW-37 was strictly dependent on the production of
ROS. Thus, both, Tiron and Trolox completely blocked the cytotoxic activity of the
TW-37/CI-1040 combination in melanoma cells (Figure 11B).
CI-1040 has been previously used as the proof of principle for blocking MEK
in human melanoma cells grown as mouse xenografts (50). Therefore, we used this
compound to validate our hypothesis that BH3 mimetics targeting Mcl-1,

B c 1-x l

and

Bcl-2 can significantly improve the therapeutic impact of MEK inhibition in vivo,
even in otherwise chemoresistant melanoma cells expressing NRAS mutations.
Towards this end, SK-Mel-103 were transduced with GFP (to aid in non-invasive
imaging of tumor growth) and injected s.c. in immunosuppressed mice (Figure 11CF). Animals were treated with suboptimal concentrations of TW-37 and/or CI-1040
(to mimic unfavorable situations that may be encountered in human tumors) and
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monitored for tumor growth at different times post-implantation. Consistent with the
synergistic tumor-cell killing culture, the MEK inhibitor/TW-37 combination was
found to block melanoma cell growth in mice as shown by a significant reduction in
tumor volume and tumor mass (Figure 11C,D; see representative examples of placebo
and drug-treated animals in Figure 11E, F). In summary, our results identify a new
BH3 mimetic (namely, TW-37) as a potent strategy to overcome melanoma
chemoresistance. Thus, rationally designed BH3 mimetics may broaden the spectrum
of patients that could benefit from available inhibitors of the MAPK pathway.
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Figure 11 continued. Synergy between TW-37 and MEK inhibitors is not restricted to U0126
and can be visualized in vivo. C to F, effect o f TW-37 and MEK inhibition on melanoma growth
(mouse xenografts). C, comparative analysis o f the localized growth o f melanoma cells (line SKMel-147) implanted s.c. in immunosuppressed mice. Points, mean tumor volume in animals treated
with placebo control (gray diamonds), TW-37 (gray squares), the MEK inhibitor CI-1040 (black
triangles), or a combination o f both agents (white squares); bars, SE. Pairwise comparisons among
groups were analyzed with the Tukey’s HSD test. *, P < 0.05, statistical significance with respect
to untreated controls or the indicated drugs as single agents. D, tumor weight estimated for the
indicated treatment groups at day 20 after implantation. The Dunnett test was used for individual
comparisons to untreated controls. *, P < 0.05. E, representative photographs captured with visible
light o f animals corresponding to each treatment group at day 20 after tumor cell injection. F,
noninvasive visualization o f GFP-tagged tumor cells by whole-body fluorescence imaging showing
a significant reduction in tumor size by the TW-37/MEK inhibition combination.
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Discussion
Here, we describe an unexpected interplay between the MAPK pathway and
anti-apoptotic factors in the control of melanoma cell viability. Moreover, we report a
new strategy to activate the intrinsic expression of p53 in melanoma cells by
exploiting their intrinsic sensitivity to ROS. This study capitalizes on stable RNA
interference to define the specific role of single proteins in an otherwise intrinsically
complex genetic background o f tumor cells.

By combining pharmacological

approaches with selective downmodulation of Bcl-2, Bcl-xL, Mcl-1, BAX, BAK and
p53, we were able to (i) identify mechanisms o f resistance to MEK inhibitors, (ii)
provide the rationale for a pleiotropic BH3 mimetic (TW-37), (iii) address the mode
of action of this compound and (iv) define a differential regulation o f ROS production
in melanocytes and melanoma cells.
Dissecting the molecular basis underlying the regulation of the MAPK
pathway and Bcl-2 family members has important translational implications. The
potentially “druggable” nature of both signaling cascades (14, 15, 43) and the fact
that they are invariably dysregulated in melanoma cells, have inspired efforts aimed
at the development of molecularly targeted therapies. Unfortunately, improved
antitumor efficacy and reduced secondary toxicity from novel therapies has not yet
been demonstrated in clinical settings (28). Certainly, multiple factors may contribute
to marginal effects o f current therapeutic agents. Limited solubility and stability of
the compound(s) as well as increased drug efflux pumps or detoxification enzymes
are some examples o f factors that may compromise the bioavailability of anticancer
drugs in melanoma cells (5, 7). Our results support the notion that melanoma cells
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may be more resistant than other tumor cells by virtue of diversifying the regulation
of death mediators, for example by reducing the number of anti-apoptotic proteins
controlled by the same transcription factor. Thus, ERK-independent expression of
Mcl-1,

B c 1-x l

and Bcl-2 (Figure IE) can provide a potent fail-safe mechanism for the

maintenance of melanoma cell viability after RAS, BRAF or MEK inhibition.
Conversely, ERK-dependent downregulation of apoptotic activators of BAX/BAK
(e.g. BimEL), and the expression of survivin can prevent the induction o f cell death by
BH3 mimetics.
In the context of mechanistic analyses of cell death, TW-37 also sheds light
on the requirements for the activation of the apoptotic machinery in melanoma cells.
The molecular basis of the resistance to standard chemotherapeutic agents remains
unclear (5, 7, 28). Extrapolating from other tumor types has been complicated
because o f a debated controversy on the hierarchical organization o f Bcl-2 family
members. Specifically, a major point of contention has revolved around the activation
of BAX and BAK (47, 51). Two models have been described depending on how BAX
and BAK become activated once they are released from anti-apoptotic Bcl-2
members. According to the so-called “displacement model”, the default state o f BAX
and/or BAK is an active conformation able to directly cause release of proapoptogenic factors from the mitochondria (52, 53). In this setting, BH3 mimetics are
expected to be highly effective since they would bypass the requirement for
additional upstream activators o f the mitochondrial pathways (i.e. Bim, Bid or p53),
which are frequently compromised in tumor cells.
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The “direct binding model” argues that removal of anti-apoptotic proteins is
not sufficient to promote cell death and that additional pro-apoptotic inducers are
required for full activation of BAX and BAK (51, 54). Our data are consistent with
this second model since low doses of TW-37 or inactivation o f Bcl-2,

B c 1-x l

or Mcl-

1 by RNA interference were unable per se to engage the apoptotic machinery in
melanoma cells. These results may account, at least in part, for the failure of Bcl-2
antisense strategies as monotherapy in melanoma (55). Taken at face value, our
results would not even support the use of pleiotropic BH3 mimetics as single anti
melanoma agents. However, it should be emphasized that the very need for
cooperative signals provides the basis for tumor cell selectivity. We propose
MEK/ERK inhibition as an effective strategy to accelerate the kinetics and efficacy of
BH3 mimetics. Thus, the induction o f BimEL and reduction o f survivin by U0126
together with the synergistic effect of U0126 and TW-37 on p53, could provide the
required signals for the activation of BAX/BAK and the subsequent induction cell
death in otherwise chemoresistant melanoma cells.
Perhaps one of the most intriguing results of this study is that the synergy
between TW-37 and the inactivation of MEK/ERK relies on a tumor-cell restricted
induction of p53 via ROS. Functional interactions between p53 and MAPK pathways
have been described in a variety of systems. Thus, the MAP kinases, ERK, JNK and
p38 can play an active role in the phosphorylation and induction of p53 (56).
However, in melanoma cells treated with a BH3 mimetic, we found the opposite
situation: inhibition of MEK/ERK favored an efficient accumulation and activation of
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p53. Future studies will determine the specific impact of ROS on p53 function, but it
may correspond to direct activation by oxidation (57).
Importantly, the TW-37/U0126 combination offers several advantages. First,
the induction of p53 by TW-37/U0126 is tumor-cell selective. This is in contrast to
stimuli such as UV and y-radiation, as well as various DNA-damaging drugs
including Adriamycin, etoposide or cisplatin among others, which affect p53 levels
both in normal and tumor cells (12, 32). By avoiding the activation of p53 in normal
cell compartments TW-37/U0126 could reduce the secondary toxicity characteristic
of standard anti-tumor therapies. A second attractive feature of TW-37/U0126 is that
it may exploit transcription-independent functions of p53 and thus bypass defects
required for DNA binding (51). Thus, BAX and BAK activation were observed
independently o f significant increases in total protein expression (Figure 8C,D).
Furthermore, TW-37/U0126 can efficiently bypass defects downstream of the
mitochondria. O f note, the melanoma lines used in this study express low levels of
Apaf-1 and high levels of caspase inhibitors (e.g. XIAP, ML-IAP) (31, 58). These
genetic defects, which can reduce the sensitivity to adriamycin, placlitaxel or high
doses of etoposide (58-61), did not prevent cell death by TW-37/U0126.
Finally, the TW-37/U0126 treatment revealed an intrinsically different
threshold for the accumulation and control of changes in ROS between normal
melanocytes and melanoma cells. Melanocytes are specialized pigment-producing
cells. They produce melanin, which is inherently adapted to scavenge ROS and thus
prevent DNA damage, recruitment of stress-associated transcription factors, and the
initiation of apoptosis (62). Paradoxically, this protective function o f melanin is
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frequently lost during tumor progression (63). Consequently, melanoma cells may be
more sensitive than melanocytes to ROS-induced cell death (64). The accumulation
of ROS following U0126 in melanoma cells treated with TW-37 indicate that the
MEK/ERK MAPK pathway may play an additional mechanism of control of
melanoma viability under ROS-inducing stress stimuli.
In conclusion, here we have shown a potential therapy for melanoma based on
the capacity of a novel, pleiotropic BH3 mimetic (TW-37) to synergize with MEK
inhibition (U0126). We have shown that melanoma cell death is dependent not only
on the activation of BAX/BAK as expected from a BH3 mimetic, but a tumor-cell
selective induction of a ROS-p53 feedback loop upstream of the mitochondria.
Therefore, this combination therapy may prove especially beneficial for melanoma,
since p53 is rarely mutated in this tumor type (5). The TW-37/U0126 combination
takes full advantage of intrinsic dysregulated redox capacity of melanoma cells and
highlights ROS as a point of vulnerability of melanoma cells that can be exploited for
drug development.
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